**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 69932

**Manuscript Type:** REVIEW

**Adipose tissue in bone regeneration - stem cell source and beyond**

Labusca L. AT in bone regeneration

Luminita Labusca

**Luminita Labusca,** Magnetic Materials and Sensors, National Institute of Research and Development for Technical Physics, Iasi 700050, Romania

**Luminita Labusca,** Orthopedics and Traumatology, County Emergency Hospital Saint Spiridon Iasi, Iasi 700050, Romania

**Author contributions:** Labusca L drafted the manuscript, revised the literature and wrote the manuscript text.

**Corresponding author: Luminita Labusca, MD, PhD, Senior Scientist,** Magnetic Materials and Sensors, National Institute of Research and Development for Technical Physics, Boulevard Dimitrie Mangeron 47, Iasi 700050, Romania. drlluminita@yahoo.com

**Received:** July 17, 2021

**Revised:** August 30, 2021

**Accepted:** May 27, 2022

**Published online:** June 26, 2022

**Abstract**

Adipose tissue (AT) is recognized as a complex organ involved in major homeostatic body functions, such as food intake, energy balance, immunomodulation, development and growth, and functioning of the reproductive organs. The role of AT in tissue and organ homeostasis, repair and regeneration is increasingly recognized. Different AT compartments (white AT, brown AT and bone marrow AT) and their interrelation with bone metabolism will be presented. AT-derived stem cell populations - adipose-derived mesenchymal stem cells and pluripotent-like stem cells. Multilineage differentiating stress-enduring and dedifferentiated fat cells can be obtained in relatively high quantities compared to other sources. Their role in different strategies of bone and fracture healing tissue engineering and cell therapy will be described. The current use of AT- or AT-derived stem cell populations for fracture healing and bone regenerative strategies will be presented, as well as major challenges in furthering bone regenerative strategies to clinical settings.

**Key Words:** Adipose tissue; Bone metabolism; Fracture healing; Adipose-derived stem cells; Multilineage differentiating stress-enduring; Dedifferentiated fat cells; Bone engineering

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Labusca L. Adipose tissue in bone regeneration - stem cell source and beyond. *World J Stem Cells* 2022; 14(6): 372-392

**URL**: https://www.wjgnet.com/1948-0210/full/v14/i6/372.htm

**DOI**: https://dx.doi.org/10.4252/wjsc.v14.i6.372

**Core Tip:** Adipose tissue (AT) is a multifunctional organ with intricate body functions. Different AT compartments have complex interrelations with bone metabolism, tissue maintenance and fracture healing. AT-derived stem cell populations are promising tools for bone regeneration. The current use of AT- or AT-derived stem cell populations for fracture healing and bone regenerative strategies will be presented, as well as major challenges in furthering bone regenerative strategies to clinical settings.

**INTRODUCTION**

Adipose tissue (AT) has multiple roles in body energy balance, regulation of food intake, immunomodulation and growth and functioning of the reproductive organs[1]. In recent years, the understanding of AT functioning has evolved from considering it a lipid storage, cushioning and thermal insulating mass to its recognition as the largest endocrine organ within the mammalian body[2]. AT-derived signaling molecules, adipokines and cytokines have a crucial role in local and systemic regulation by controlling energy expenditure, glucose homeostasis, insulin metabolism and immune cell function to support cell proliferation in normal and pathological states. AT has received increased attention in recent years mainly due to its abnormal expansion in obesity and metabolic syndrome. Normal AT has intricate roles in maintaining healthy body functioning. Not surprisingly, obesity is very often accompanied by many endocrine and metabolic disturbances, such as insulin resistance, type 2 diabetes mellitus (T2D), disorders in immune regulation and response to pathogens, and tumor occurrence, progression and metastasis[3]. The pathological lack of AT (congenital, human immunodeficiency virus - or age-related lipodystrophy) is linked to multiple metabolic and immune abnormalities, such as insulin resistance, liver steatosis and dyslipidaemia[4]. Given its multifaceted roles in controlling body homeostatic mechanisms, AT involvement in tissue and organ healing and regeneration is complex and only partially recognized. Understanding AT involvement in regeneration and repair is a relatively new concept. Consistent research in recent decades has focused on AT as a mesenchymal stem cell source. Pluripotent stem cells extracted from white AT (WAT) under special conditions together with transdifferentiated adipocytes have the potential to accelerate progress in the field of bone engineering. AT, with its complex paracrine and endocrine signaling and angiogenetic potential, might also be used to support the bone regenerative niche. The types of AT - WAT, brown (and beige) AT (BAT) and bone marrow AT (BMAT) - will be very briefly introduced with emphasis on BMAT given its direct involvement in bone metabolism. Current strategies that employ AT or AT-derived cell populations for fracture healing or bone regeneration will be presented.

**WAT IS A COMPLEX ENDOCRINE ORGAN**

In humans, WAT is formed starting from the second semester of gestation and continues throughout life, even in adults[5]. In mice, WAT adipocytes are derived from mesenchymal progenitors within the somites or lateral plate mesoderm, which could be the case for humans[6], except for minor fat deposits of the skull derived from the ectodermal neural crest[7]. WAT therefore shares a developmental origin with all the components of connective tissue (muscle, bone, tendon and fascia). WAT is composed of mature cells (adipocytes) that contain unilocular deposits of lipids (triacylglycerol) occupying up to 90% of the cytoplasm. Only one-third of the tissue is represented by mature adipocytes, and other cellular components are preadipocytes, stromal cells, mesenchymal progenitors and immune components [monocytes and macrophages (Mcfs)]. WAT represents the major energy storage system of the body and is the main lipid deposit[8]. It has a mechanical role in thermal insulation, organ cushioning and protection from trauma. In humans, mature adipocytes store lipids synthetized in the liver and, to a minor extent, within AT itself by lipogenesis, an insulin-dependent enzymatic process. Fatty acid (FA) and triglycerides (TG) availability in other organs in the case of energy demand are dependent on the activity of AT lipolytic enzymes[9]. Two main compartments of WAT are described based on their anatomic location: Subcutaneous and visceral. Their characteristic distribution is sex hormone-dependent with visceral compartment testosterone and subcutaneous oestrogen - controlled[10]. Mature adipocytes release bioactive molecules (commonly denominated adipokines) that exert paracrine and endocrine functions in maintaining body energetic metabolism, insulin sensitivity, food intake, immune modulation, haematopoiesis, bone metabolism, angiogenesis, coagulation and fibrinolysis. Adipokines are a set of cytokine (leptin, adiponectin visfatin) chemokine (nitric oxide, hydrogen peroxide) growth factors, vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and colony-stimulating factor 1 complement factors, such as adipsin, B, C, and C3[11]. It is beyond the scope of this paper to describe their role in body balance; however, it should be noted that numerous bioactive molecules released by normal mature adipocytes are among crucial factors implicated in all the stages of wound and bone healing.

WAT is a very dynamic tissue that largely fluctuates in quantity but also its functional qualities across growth, maturity and ageing, physiological stages and diseases. Obesity as a disease of excess and lipodystrophy as a sum of conditions where WAT does not form or becomes atrophic are both associated with important perturbations in adipocyte quality and functioning. In obesity, adipocytes increase in number (hyperplasia) and size (hypertrophy), while in lipodystrophy, *de novo* adipogenesis and lipid droplet formation are impaired. Obesity and lipodystrophy are accompanied by severe metabolic disorders, such as hypertriglyceridemia, insulin resistance, diabetes, and fatty liver, as well as by severe perturbation in adipokine release. Impaired metabolic status and abnormal WAT paracrine and endocrine signalling in diseases of lack and excess have consequently impaired wound and bone healing.

**ROLE OF WAT IN TISSUE REGENERATION**

WAT deposits and healthy functioning mature adipocytes are involved in homeostatic maintenance, turnover and repair of several organs and tissues, such as hair follicles, skin and mammary glands[12]. Bone morphogenetic protein (BMP) expression by mature adipocytes may be regulators of the quiescent stage of hair follicle stem cells and supportive of hair lineage specification and differentiation during hair growth[13]. Adipogenic progenitors (AP) within dermal WAT stimulate hair stem cell follicle activation. Intradermal AP injection was shown to increase the growth of hair cell follicles, while leptin expressed by mature adipocytes induced the activation of hair cell follicles and hair shaft growth[14]. Mature adipocytes are a major component of the dermis that supports the skin epithelial layer and keratinocytes. Dermal WAT was previously thought to exert a cushioning and insulating function; however, its role in supporting skin integrity and promoting wound healing is increasingly recognized and explored. Mature adipocyte-secreted adiponectin and leptin were shown to increase keratinocyte proliferation *in vitro* and to consistently increase wound re-epithelialization in mouse models[15],while adiponectin-deficient mice suffer from severely delayed wound epithelialization[16]. Adiponectin regulates local apoptosis, and its absence in diabetic subjects might explain hyperkeratosis and thickened wound margins characteristic of chronic ulcers[17]. Another adipokine, leptin, was shown to increase re-epithelialization, angiogenesis and wound contraction after injury[18]. Functional mature adipocytes are required for the third stage of wound healing and extracellular matrix (ECM) deposition by fibroblasts. Mouse strains that lack mature adipocytes have impaired fibroblast repopulation during wound healing, and incomplete ECM deposition leads to recurrent wounding in this model[19]. Mature adipocytes are required for the development of a functional mammary gland ductal tree. In lipodystrophic and inducible adipocyte loss mouse strains, mammary gland formation is impaired[20].

WAT presence within muscles is commonly associated with tissue degeneration. Muscle fatty atrophy is a frequent clinical correlation with insulin resistance and increased body max index (BMI). However, if mature adipocytes in muscle tissue are a witness of impaired muscle function, common adipogenic and fibroblast progenitor (FAP) multipotent muscle resident stromal cells are required for muscle wound healing and tissue growth. FAPs enhance the rate of differentiation of primary myogenic progenitors *in vitro* and expand during muscle injury. FAPs were shown to supply transient pro-differentiation signals for proliferating myogenic progenitor cells after muscle injury in animal models[21]. Interestingly, when FAPs are transplanted within subcutaneous or dermal tissue, they differentiate into WAT, demonstrating the role of the environment in their activation and differentiation. FAPs are present in human skeletal muscle tissue and could be the source of fatty infiltration during muscle degeneration[22]. These progenitors have dual responsiveness to environmental cues, being able to generate either adipocytes or to support muscle hypertrophy. FAPs respond to metabolic stress during metabolic disorders by conversion to adipocyte lineage, as well as mechanical stress, during physical activity by fibrogenic conversion and contribution to satellite cell activation. This response might explain their opposite role in fatty infiltration and muscle healing and hypertrophy[23].

**WAT IN BONE METABOLISM AND FRACTURE HEALING**

WAT and bone metabolism are coordinated directly by the central nervous system through sympathetic and parasympathetic innervation and indirectly by circulating hormones. Sympathetic innervation controls WAT metabolism, while the parasympathetic role in this tissue is less agreed upon. Indirectly, sympathetic innervation of adrenal glands controls glucocorticoid release. Elevated levels of glucocorticoids are clinically associated with bone loss and hypertrophic WAT expansion during obesity[24]. Ghrelin, a neuroendocrine hormone produced in the gastrointestinal tract, has a dual role in regulating white adipocyte metabolism by increasing lipoprotein lipase and FA synthase and increasing peroxisome proliferator-activated receptor-β (PPAR-β), stimulating the synthesis of TG and their mobilization. Ghrelin was found to directly promote osteoblast proliferation and differentiation, resulting in increased bone mineral density (BMD) in animal models[25]. Several WAT-released adipocytes have dual roles in bone and adipose maintenance and turnover. Leptin is known to inhibit food intake, increase energy expenditure and reduce WAT by increasing lipolysis. Leptin has a direct effect in promoting bone marrow stem cell (BMSC) differentiation to osteoblasts and preventing their adypogenic conversion[26].Leptin increases the expression of osteocalcin (OC), alkaline phosphatase and collagen I, which are required for osteoblast maturation[27].Leptin is involved in controlling bone resorption by increasing osteoclast-inhibiting osteoprotegerin (OPG)[28]. Direct administration was found to increase BMD and femur length in leptin-deficient mice[29].Adiponectin, the adipokine that is most commonly found in plasma, improves insulin sensitivity, increases the rate of FA oxidation and reduces inflammation and fatty muscle infiltration. Low levels of circulating adiponectin are found in obese and lipodystrophic mouse models[30], have been implicated in inducing insulin resistance in obese subjects and proposed as a serum biomarker for detecting metabolic syndrome[31]. Adiponectin was found to promote osteogenesis in BMSCs by indirectly increasing BMP2 expression[32], to increase alkaline phosphatase (ALP), collagen I and OC expression and to promote osteoblast proliferation and differentiation in a dose-dependent manner[33]. Similar to leptin, adiponectin inhibits osteoclast activity through distinct mechanisms. Adiponectin decreases the expression of cathepsin K and acid-resistant phosphatase, which are osteoclast regulators that increase osteoclast apoptosis[34]. Notably, the endocrine and paracrine roles of adipokines in bone metabolism are contradictory. The results from *in vitro* and *in vivo* studies are sometimes contradictory, and no direct correlation between increased levels of adipokines and supported bone metabolism could be clearly stated. Several factors could be involved, such as dosage, the timing of adipokine release and their effect in mediating inflammation[35]. It appears more likely that WAT and bone metabolism crosstalk is contextual. The presence of adipokine receptors on BMSCs and osteoblasts demonstrates that anabolic bone metabolism has a direct interrelation with WAT adipocytes. The WAT-bone catabolic interrelation is exerted through distinct pathways that regulate osteoclast formation or apoptosis.

WAT contains an important fraction of immune cells. Local AT-resident Mcfs (MATs) in normal/lean individuals display an anti-inflammatory phenotype described as the M2 (alternatively activated) phenotype, which supports WAT expansion during adaptation to a high-fat diet. Prolonged WAT inflammation, however, leads to fibrosis and ECM stiffness, hindering adipocyte expansion and lipid storage[36]. WAT expansion during obesity is associated with increased levels of macrophage chemoattractant-1, which determines the accumulation of high levels of M1 (inflammatory) MATs that can induce insulin resistance[37].Other local immune cells, regulatory T cells (Tregs), which are more abundant in lean but not obese WAT, have been shown to promote the M2 MAT phenotype, and their increase in obese WAT can improve insulin sensitivity[38].

Mcfs are present during the inflammatory phase of fracture healing in humans and animals. Compared to Mcf derived from blood monocytes, tissue-resident cells seem to have a more important role in fracture healing. Bone marrow and periosteal M1 phenotype Mcf-released cytokines [interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)] are present at the fracture site during the first days after injury in animal models and humans. M1 phenotype persistence during callus formation delays or compromises healing. Bone-specific Mcfs (osteomacs) have been involved in bone healing and remodelling; however, other Mcf tissues might also contribute[39]. Tissue-resident M1 and M2 MCfs are involved in *de novo* angiogenesis within the granulation tissue during fracture healing, as well as stem cell/progenitor cell recruitment to the fracture site and their differentiation. Oncostatin M, a cytokine of the IL-5 family produced by M1 Mcfs, was shown to induce osteoblast differentiation and matrix mineralization from human mesenchymal stem cells while inhibiting adipogenesis *in vitro*[40]. Furthermore, the number but most of all the Mcf phenotype required for fracture healing might be dependent on the type of callus formation (enchondral *vs* endosteal) and the type of fracture fixation. More detailed *in vivo* studies are required to decipher the origin of Mcf involved in fracture healing; however, these cells apparently need to switch phenotype upon environmental stimuli during the time course of bone healing. MAT involvement in bone remodeling and fracture healing needs further investigation. Delayed fracture healing during obesity and metabolic syndrome might be[41], at least in part, explained by the presence of M1MAT, which prolongs the inflammatory stage and prevents callus maturation.

**BAT**

The typical BAT is located between the shoulder blades in smaller mammals. In newborn humans, the interscapular “BAT organ” contains adipocytes that are multilocular dispersed as lipid droplets within the cytoplasm and contain numerous mitochondria that express uncoupling protein-1 (UCP-1). Their main function is to metabolize FAs for thermogenesis, protecting the body from cold exposure through non-shivering thermogenesis[42]. Two forms of BAT are currently recognized to exist in humans: Constitutional BAT (cBAT) formed during embryonic development and beige or brite (brown-in-white) BAT. The former is recruited postnatally from WAT and has been denominated recruited BAT (rBAT). cBAT of developmental origin seems to be mesoderm closer to skeletal muscle rather than to AT, while rBAT can be formed after birth by transdifferentiating mature white to brown adipocytes or by differentiation from BAP[43]. Previously considered to be represented in humans only in newborns, recent positron emission tomography/computed tomography (PET/CT) studies based on imagistic detection of UCP-1-positive adipocytes have identified functional BAT in adults. BAT seems to be more frequent in women than in men and is inversely correlated with BMI, especially for elderly subjects[44].

The main function of BAT is thermal regulation. Recently, several studies in mice revealed the role of BAT as a negative regulator of obesity since UCP-1 depletion in mice induced increased cold sensitivity and obesity[45]. Apart from connections with energy metabolism and thermal regulation, recent studies correlated BAT with bone anabolism[46]. BAT detected around the neck in the supraclavicular region and paravertebrae using functional PET-CT correlated positively with BMD in women[47] but not in men[48]. This possible sex dependence of the positive effect of BAT on bone was not confirmed in a cross-sectional study correlating BAT volume with femoral cortical bone area and cross-sectional area in children and teenagers independent of sex[49]. The transcriptional regulator and tumor suppressor retinoblastoma-associated protein (pRb) have been identified as a possible connection between bone and BAT and bone turnover. pRB functions as the switch mechanism that directs mesenchymal progenitors to the osteoblastic lineage, while deletion of pRb in the respective precursors increased the amount of BAT in mouse models[50]. BMP overexpression in soft tissues after trauma seeks to recruit brown adipocytes and induce hypoxia-mediated chondrogenic differentiation of local progenitors. Subsequent ossification of chondrogenic nodules determines the formation of posttraumatic heterotopic ossification[51].

**BAT AND BONE METABOLISM**

Consistent research is directed to finding methods of transforming white adipocytes into brown or “beige” phenotypes for the treatment of obesity and associated metabolic disorders. Overexpression of forkhead transcription factor C2 (FOXC2) in mouse WAT cells induced a BAT-like phenotype[52]. Genetically modified mice that overexpress FOXC2 were found to not only be protected against diet-induced obesity and insulin resistance but also have increased trabecular bone mass and bone turnover[53]. BAT-bone metabolism could be correlated through secreted paracrine factors. AT and BMAT overexpressing FOXC2 displayed increased gene expression of endocrine factors adiponectin, insulin growth factor receptor 3 (IGFR2) and IGF1, as well as paracrine factors BMP4, wingless-type MMTV integration site family member 10B and angiopoietin 2. Human endolymphatic sac epithelial factors were shown to exert a pro-osteoblastic effect *in vitro* and could represent the modality of BAT-bone communication and bone anabolic support[46].

**BMAT - A UNIQUE TYPE OF AT**

Bone marrow contains a fraction of AT that fluctuates during development, growth, ageing and pathological conditions. While this fact is common knowledge, the origin, role and functions of BMAT remain largely unknown. More closely resembling WAT, which shares several microstructural commonalities[54], BMAT has a particular molecular make-up that distinguishes it from WAT and BAT[55]. The unicity of BMAT seems to be related to not only its particular anatomic location and spatial constraints but also its involvement in body functioning as a whole[56]. BMAT-released adipokines, inflammatory cytokines and other possible bioactive molecules are thought to exert systemic regulatory effects. Recent years have witnessed a surge in experimental investigations that challenge the passive role of BMAT as a simple space filler within the bone marrow microenvironment. The onset and progression of postmenopausal osteoporosis in the context of oestrogen depletion[57], glucose homeostasis, energy metabolism[58], or adipocyte-osteoblast balancehave been recently linked with BMAT reactivity[59]. These investigations point towards BMAT involvement in structural changes occurring within the skeleton with age during physiological and pathological situations and as a key player in the maintenance of body energetic expenditure.

**STRUCTURE AND COMPOSITION OF BMAT**

In healthy adults, BMAT represents approximately 10% of the total body AT. While the presence of adipocytes within the complexity of the bone marrow tissue environment was detected a century ago, only recently was their role as a local and systemic regulator explored[60]. The availability of methods for *in vivo* quantification and the use of reporter transgenic mice combined with experimental induction of BMAT expansion have enabled recent insights into its function. The correlation of BMAT expansion with metabolic diseases, such as obesity, metabolic syndrome, diabetes and anorexia nervosa, is sought to point towards a role in systemic metabolic balance. Unlike any other form of AT, BMAT has physical vicinity at a cellular level with bone tissue. BMAT expansion is associated with decreased bone mass and osteoporosis experimentally, as well as in epidemiological studies[61]. Multiple factors are involved in this correlation, such as bone marrow mesenchymal stem cell adipogenic *vs* osteoblastic conversion, adipokine release or inflammation. BMAT is also involved in normal and pathological haematopoiesis through adipocyte cellular interaction with haematopoietic progenitors and local adipokine release[62]. BMAT adipocytes are responsive to producing and sustaining a local inflammatory environment that impacts *de novo* bone formation and favors malignant conversion of haematopoietic lineages or tumor metastasis to bone[63].

Considered to originate from bone marrow mesenchymal progenitors, BMAT adipocytes are unilocular similar to WAT and can be found within the bone marrow cavity of bones. In young individuals in humans and mice, bone marrow has a red appearance and contains predominately haematopoietic and osteoblast progenitors, as well as erythroid cells. Macroscopically, bone marrow becomes yellow with a fatty structure upon BMAT development. Using magnetic resonance imaging, in human subjects, progression of red to yellow marrow was observed in the long bones (the femur) first in the diaphysis (ages 1-10 years) and then in the distal metaphysis (ages 10-20 years), with an adult pattern seen by age 24 years[64]. BMAT first develops in the distal appendicular skeleton (femur, tibia) compared to the proximal and caudal vertebrae (tail bones) compared to the proximal (thoracic) vertebrae. In rats, differences were attributed to cold exposure, as well as strong erythropoietin stimuli, since retaining warm temperature, as well as induced haemolysis, prevented bone marrow “yellowing” in pre-weanling but not in mature animals. This led to the conclusion that BMAT once formed is a stable tissue[65]. Two developmental and regional distinct BMAT subtypes have been identified. The distal localized, first to develop, was denominated the constitutive (cBMAT), while the proximal placed (within proximal limbs, thoracic vertebrae, hips, ribs) later occurring and more scattered was denominated the regulated (rBMAT). cBMAT was found to contain predominately unsaturated lipids, while rBMAT contains saturated fats. It has been proposed that rBMAT can mature into the more stable cBMAT phenotype under certain conditions[57].

**ROLE OF BMAT IN BONE METABOLISM AND FRACTURE HEALING**

BMAT adipocytes are a major participant in the BM niche alongside BMSCs and hematopoietic stem cells. Their physical presence, as well as endocrine and paracrine function, impacts osteoblast and osteoclast differentiation and functioning[66]. Several mechanisms for BMAT adipocyte involvement in the maintenance of bone anabolic-catabolic balance have been proposed.

Since osteoblasts and adipocytes share a common precursor, the most important factor in regulating bone formation is intrinsic BMSC “fate decision”. Lineage determination is controlled on one side by signalling pathways that promote expansion of one lineage *vs* another and on the other side by suppression of pathways promoting the competitive lineage. Bone formation occurs by inducing osteogenic key regulators runt-related transcription factor 2 (RUNX2) and osterix in MSCs while inhibiting adipogenic PPAR-γ and CCAAT/enhancer-binding protein α *via* a Wingless-type MMTV integration site family (Wnt) mechanism[67]. Conversely, adipogenesis requires concomitant induction of key adipogenic pathways and inhibition of osteogenic Wnt and Notch[68]. In BMSCs, intracellular accumulation of proteins that induce adipogenesis, such as transducing-like enhancer of split 3, increases the expression of PPAR-γ and suppresses Wnt-induced β catenin accumulation and RUNX by a histone deacetylase mechanism[69]. Increased BMSC adipogenic conversion and reduced osteoblast formation are considered the main culprits for compromised bone anabolism and BMAT accumulation[70]. It is currently accepted that an increase in BMAT during ageing, osteoporosis, and T2D is associated with decreased bone quality and quantity (osteoporosis, osteopenia). However, this inverse correlation is not confirmed by all clinical situations. Epidemiological studies confirm increased BMAT in osteoporotic patients compared to age-matched controls in children, young adults and elderly individuals[71,72]. Increased BMAT was found to correlate with increased BMD in obese and T2D patients[73]. Furthermore, decreased BMD and increased BMAT content in anorexia nervosa are associated with decreased BMI in anorexia nervosa patients[74]. These findings suggest that BMD might not be the ultimate predictor of bone quality and that BMSC adipogenic and osteoblast conversion might not be mutually exclusive[75]. Lineage tracking of adult adipocyte BMAT is warranted to elucidate their origin, as well as potential competition with osteoblast differentiation and maturation.

The BMAT-bone relationship does not resume cell fate decisions. MAT-released adipocytes (especially leptin and adiponectin), inflammatory cytokines (which include TNF-α and the IL family) and mRNA-containing extracellular vesicles (EVs) form a complex signalling network involved in regulating osteogenesis[76]. It is worth mentioning that studies on AT-released factors and their influence on bone metabolism largely involve WAT adipocytes. Few studies specifically address the molecular mechanisms of BMAT adipocyte-secreted signalling molecules and their role in bone metabolism.

No direct evidence exists regarding the association between BMAT and fracture risk and fracture healing. Indirect observation is provided by studies on fracture healing in obese experimental models of human subjects that could have increased BMAT. Experimental studies on obese mice reported an increased incidence of delayed union associated with increased callus adiposity in obese T2D mice[77,78]. A meta-analysis of eight epidemiologic studies including 39938 participants concluded that metabolic syndrome has no explicit effect on bone fractures[79]. In another study, obesity was not associated with an increased incidence of nonunion after ankle fractures[80],while yet another study reports a greater risk of complications in obese patients[81]. Multiple confounders, such as the association of alcohol consumption, T2D, and quality of fixation, can explain these contradictory results. Another possible indirect indication comes from the studies reporting increased fracture healing in patients with long bone fractures fixed with reamed intramedullary rods *vs* non-reamed patients. This finding can be explained by the stability of fixation, preservation of fracture haematoma that favors formation of periosteal callus or activation of MSC recruitment[82], rather than by mere removal of BMAT.

**AT IN BONE REGENERATIVE MEDICINE**

Regenerative medicine (RM) aims to completely restore functionality and anatomy in degenerating or ageing tissues or to replace tissues and organs lost to trauma, infection, tumor removal or congenitally absent[83]. RM makes use of cells, especially stem cells, bioactive molecules and supportive/functional ECM equivalents, to induce regeneration or engineer implantable bioequivalent structures. Recent decades have witnessed a surge in regenerative interventions for improving bone health, aiming to increase bone quality and prevent or treat failures in fracture healing. Several cell types of use for RM purposes can be obtained from AT, and adipose-derived mesenchymal stem cells (ADSCs) and adipose-derived pluripotent stem cells will be briefly described in the following subchapters.

**ADSCS**

AT is considered a convenient source of mesenchymal stem cells because of its ease of procurement and abundance of colony-forming units. Compared to adult bone marrow, the frequency of ADSCs obtained per tissue unit can be up to 500-fold higher[84]. AT can be obtained by minimally invasive procedures (subcutaneous lipectomy) or as a byproduct of cosmetic liposuction procedures. ADSCs were first obtained from subcutaneous WAT lipoaspirate by enzymatic digestion and selection of plastic adherent cell populations[85]. Enzymatic digestion of lipoaspirate or WAT fragments obtained by lipectomy or mechanical cell extraction from the same sources derives the stromal vascular fraction (SVF). SVF is a cell mixture that contains preadipocytes, fibroblasts, vascular cells, blood cells and Mcfs that can be readily used for regenerative purposes. ADSCs are obtained from the SVF by further cultivation and selection of mesenchymal progenitors based on their adherence to tissue culture. The anatomic location of harvest (such as abdominal, brachial, inguinal) position (superficial subcutaneous *vs* deep hypodermic), age and sex of the donor influence the number of mononuclear cells extracted and the number of ADSCs obtained from subcutaneous WAT[86]. ADSCs meet the criteria established by the International Society for Cell Therapy for defining mesenchymal progenitors (plastic adherence, trilineage mesenchymal differentiation and surface marker phenotype)[87]. It has been reported that the SVF contains four different mesenchymal cells or progenitors or that the putative ADSCs are CD31-, CD34+/-, CD45-, CD90+, CD105-, CD117- and CD146-, the others being pericytes (CD146+/CD31-/CD34-), mature endothelial cells (CD31+/CD34-), progenitor endothelial cells (CD31+CD34+), and preadipocytes as CD31-/CD34+ cells[88]. ADSCs were reported to differentiate under controlled conditions *in vitro* to mesenchymal lineages (adipocytes, chondrocytes, osteoblasts and cardiomyocytes[89] and skeletal muscle[90]). Ectodermal (neurons, glia and Schwan cells) and endodermal (hepatocytes and pancreatic beta islet cells) ADSC conversion has been obtained[91]. A subset of ADSCs was shown to express markers of pluripotency (Sox2, Nanog, and OCT4) and to differentiate into mesodermal and extramesodermal lineages, especially when cultured in three-dimensional suspension culture[92]. An important feature of putative ADSCs is their growth factor and immunomodulatory cytokine release. ADSCs were found to express multiple growth factors, of which basic fibroblast growth factor (bFGF), VEGF, insulin-like growth factor 1, HGFs, and transforming growth factor (TGF)-β1 but as well β-nerve growth factor, stromal cell-derived factor-1α and growth factor receptors. Mass spectrometry analysis of the ADSC secretome revealed that ADSCs express 342 proteins under normoxic conditions. These proteins were found to be related to angiogenesis and blood vessel expansion, ECM formation, cell adhesion/migration, cell survival/death, and immune regulation with little variation after hypoxic preconditioning[93]. Importantly, the ADSC secretome varies upon stimulation. bFGF or epidermal growth factor (EGF) preconditioning significantly increases ADSC release of HGF, a cytokine involved in haematopoiesis, vasculogenesis, and mammary epithelial duct formation[94]. Neural growth factor preconditioning increased the axonal growth capability of a conditioned medium from ADSCs[95]. It has been proposed that preconditioning ADSCs using low oxygen content, generation of reactive oxygen species (ROS) and activation of platelet-derived growth factor (PDGF) receptor signalling can increase the regenerative proprieties of cultivated ADSCs by mimicking the *in vivo* regenerating niche[96].

Inflammatory cytokine release varies upon ADSC stimulation. Exposure to lipopolysaccharides induced the release of haematopoietic (granulocyte/monocyte, granulocyte, and macrophage colony-stimulating factors, IL-7) and proinflammatory mediators (IL-6, IL-8, and IL-11, TNF-α)[97]. Under normal culture conditions, conditioned medium from ADSCs reduced the production of TNF-α, NO and prostaglandin E2, and the activation of nuclear factor-kappaB in blood-derived monocytes decreased their degranulation, phagocytic activity and migratory ability. Notably, using next-generation sequencing, cultivated ADSCs were found to have a more homogenous immunomodulatory gene expression profile than SVF in the natural state and upon TNF-α stimulation[98]. Trophic and immunomodulatory factors released by cultivated ADSCs are strongly influenced by a large variety of factors, such as WAT origin, donor age and health status, cell culture and preconditioning[99-101] (for a summary, see Table 1). While this influence opens large possibilities in manipulating cell therapeutic qualities, it calls for thorough characterization when an ADSC-based product is envisaged.

Given their phenotypic characteristics, ADSCs are intensively sought for their differentiation and tissue trophic and immunomodulatory potential. ADSCs can be used as building blocks for *de novo* bioengineered organs and are currently tested for the generation of musculoskeletal tissues[102,103].Cell therapy using ADSCs has proven useful in preclinical settings for immunomodulation in autoimmune diseases (such as inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis)[104]. With the recent coronavirus disease 2019 pandemic, ADSCs have been tested in emergency clinical trials for the prevention of severe “cytokine storm” and the installation of acute respiratory distress syndrome, septic shock, and/or multiple organ failure[105].

ADSCs have been intensively tested *in vitro* and in preclinical studies for their direct contribution by differentiation to the osteoblastic lineage, for their supportive effect in promoting osteogenesis and for accelerating fracture healing. Deriving from these distinct roles in RM, bone tissue engineering using ADSCs as cell sources and cell therapy for the treatment of problematic bone healing, bone pathology and systemic osteoporosis are possible therapeutic scenarios.

**DIRECT EFFECT OF ADSC IN REGENERATION - OSTEOBLASTIC DIFFERENTIATION AND TISSUE-ENGINEERED BONE STRUCTURES**

Numerous reports exist regarding the *in vitro* osteogenic potential of ADSCs under defined differentiation media, and osteogenic conversion is assessed based on specific gene expression (OC, core-binding factor subunit alpha-1, also known as RUNX2, AP, osteonectin, osteopontin, BMP-2, ALP activity and mineralized ECM deposition)[106]. Mechanical stimulation by dynamic compression or magnetic nanoparticle-induced remote actuation has also been reported to increase *in vitro* osteogenesis[107,108]. To assess ADSC osteogenic potential *in vivo*, several methods have been validated starting from ectopic bone formation in small animal models (rat, mice) after intramuscular delivery of osteogenic-induced ADSCs[109]. More complex models consist of healing experimentally induced calvarial bone defects in rodents or long bone fractures[110,111]. Generally, *in vivo* testing of ADSC osteogenic potential requires the use of a supportive structure for cell implantation. This strategy realizes a tissue-engineered implantable structure with variable degrees of complexity and potential for clinical translation. The classical “tissue engineering triad” is based on the use of scaffolds, cells and bioactive molecules to generate implantable bioequivalent tissues or organs. For bone engineering, the biomaterial needs to fulfil the general requirements for a scaffold structure (biocompatibility, biodegradability, porosity and interconnectivity of the pores, not to generate inflammatory response *in vivo*). In addition, this material needs to be osteoconductive (to allow bone mineral and collagen deposition) and osteoinductive (to favor osteogenic differentiation). Three main types of biomaterials have been used for scaffolds in bone tissue engineering: Ceramics (such as tricalcium phosphate, hydroxyapatite and combinations) and synthetic polymers [such as polylactic acid, polyglycolic acid (PGA), and poly-DL-lactic-co-glycolic acid]. Natural polymers, such as collagen, hyaluronic acid, chitosan, fibrin, and elastin, have been used alone or in combination with synthetic polymers or with ceramics[112].Alongside the osteoconductive and osteoinductive properties, biomaterial osteointegration is crucial for the stability of the engineered graft. Osteo integration is dependent on blood vessel colonization from the surrounding host tissue that allows for nutrient supply, waste removal and erasing of implant host interfaces that impede mechanical stability. Especially in the case of larger constructs, the biomaterial needs to be angioconductive and permissive to vascular in growth. Angioinduction, the ability of a biomaterial to actively induce and sustain the formation of new vessels, is another determinant of osteointegration accounting for adequate vascular supply and long-term stability of the engineered bone[113].

Advanced nanostructured materials with remarkable properties are promising for revolutionizing the field of bone engineering. Graphene, with its high surface area, high mechanical strength, and high functionalization potential, can induce ADSC differentiation even in the absence of osteogenic media. The feasibility of generating mechanically stable graphene-based implantable bone grafts and the *in vivo* osteoinductive capabilities of these implants need to be further tested[114].

Bioactive molecules largely employed for bone tissue engineering are osteoinductive growth factors from the BMP family. BMP-2 was clinically approved by the Food and Drug Administration for spine fusion, and BMP-7 was given a device exemption for the treatment of nonunions. As a result, many studies began investigating BMP as a modality to enhance ADSC-based osteogenesis *in vivo*, envisaging smoother clinical translation. However, since activation of the BMP pathway in ADSCs induces osteogenesis and adipogenesis, the use of BMP alone cannot always account for the desired fate decision. To shift the balance towards osteogenesis, switches such as the Wnt and extracellular signal-regulated kinase pathways and the ratio between BMP receptors bone morphogenetic protein type IA receptor (BMPR-IA)/BMPR-IB are at play. Controlling the sequential cascade of growth factor availability *in vivo* can prove to be technically challenging. Several methods, such as controlled release, scaffold-mediated release, gene transfer technologies or stimulation of endogenous BMP activation, have been proposed[115].

Several growth factors relevant for osteogenesis, such as b-FGF or FGF-2, IGF-1, PDGF-BB, and VEGF, are contained in platelet-rich plasma (PRP), a blood-derived biologic that is easy to procure from autologous sources. PRP incorporated within composite hydrogel-ceramic scaffolds yielded increased osteogenic ADSC conversion in a rabbit calvarial model compared to non-PRP-treated implants[116]. Different strategies of PRP coating of synthetic electrospun scaffolds appear promising, awaiting further tests for *in vivo* validation of the procedure[117]. Alternatively, overexpression of different transcription factors in ADSCs (RUNX2, VEGF, sonic hedgehog, and LIM mineralization protein) was shown to increase osteogenic differentiation and could prove an efficient strategy for inducing bone formation *in vivo*[118].

Another strategy of GF delivery could be *in vitro* cell preconditioning with osteoinductive molecules. FGF2-pretreated human ADSCs showed enhanced *in vivo* osteogenic potential in an ectopic bone model and increased osteoid formation in a dose-dependent manner[119]. Exosomes are EVs of endosomal origin, ranging from 50-200 nm in diameter, that function as intracellular communication tools. MSCs, especially ADSC EVs, contain cell-specific proteins (cytoskeletal proteins, transmembrane proteins, and heat shock proteins), nucleic acids [DNA, mRNA, micro RNA (miRNA), long and short noncoding RNA], lipids, and enzymes. EVs are recognized as bioactive cargoes with importance for cell recruitment, migration, proliferation, and *de novo* vascularization and have an important impact on tissue regeneration[120]. ADSC-derived EVs have been investigated as potential tools for inducing osteogenic differentiation. The PLDA/PGA matrix slowly released EVs from osteogenic-induced ADSCs and was shown to promote osteogenesis of BMSCs *in vitro*. Furthermore, cell-free PLDA/PGA-EV increased osteogenesis in a mouse calvarial model compared to the PLDA/PGA matrix only[121]. EVs from osteogenic-induced ADSCs could promote osteogenesis in undifferentiated ADSCs. Remarkably, ADSCs could incorporate EVs faster than BMSCs (6 h compared to 48 h), which could be of importance for therapeutic applications. Even though the study was not validated *in vivo*, the authors performed microarray gene expression and bioinformatics analyses, revealing that the differentially expressed exosomal miRNAs from osteogenic-induced ADSCs compared to undifferentiated ADSCs are involved in the osteogenetic process (the MAPK, Wnt, and TGF-β signalling pathways). The expression levels of miR-130a-3p, which blocks SIRT7, an antagonist of the Wnt pathway, were found to be significantly higher in EVs from osteogenic ADSCs. MiR-130a-p ultimately upregulates the Wnt pathway, possibly acting as the molecular mechanism of increased ADSC osteogenic induction by EVs[122].

Given their increasingly recognized role in modulating osteogenesis, miRNAs or inhibitors have been tested for inducing ADSC differentiation. Scaffold-mediated release to ADSCs or virus-transfected miR-148b, miR-26a, miR-135, or miR-130a-3p was found to increase bone formation *in vitro* and *in vivo*[123,124]. Other miRNAs, such as miR146a, miR-17, miR-23a, and miR-31, were found to inhibit BMP2-induced osteogenesis, suppressing downstream factors in BMP-2-induced osteogenesis (such as RUNX2, Osterix, and SMAD1/4). Antisense inhibition of these miRNAs in ADSCs seeded on a β-tricalcium phosphate scaffold was found to increase bone volume and BMD and to decrease scaffold residue persistence in critical size bone defects in rats[125].

Mechanical stimulation is crucial for obtaining bioengineered structures, especially in the case of musculoskeletal components. Functional tissue engineering is set to obtain robust bioequivalents that readily restore the morphology and load-bearing and motion capabilities of bone. A variety of mechanical loading procedures that apply cyclic hydrostatic pressure or tensile strain in dynamic culture conditions have been used to increase ADSC osteogenesis[126]. Magnetomechanical stimulation using magnetic nanoparticles internalized by ADSCs and magnetic field exposure during the first phases of osteogenesis has been reported as a modality to deliver remote controlled and device-free mechanical stimulation[108] (Figure 1).

A consistent number of preclinical studies have reported the use of various combinations of supportive structures, bioactive molecules and/or functional loading for testing ADSC osteogenic capability *in vivo*. Reports about the successful use of ADSC-based tissue-engineered bone are abundant in the literature[56]. Despite these encouraging results, translation to clinical settings has proven more difficult. The first report of clinical use was made in 2004 and involved ADSC use in a paediatric patient. A large calvarial posttraumatic bone defect was treated with autologous ADSCs and iliac crest cancellous bone autografts, fibrin glue and resorbable macroporous sheets[127]. In the years to follow, several case reports emerged regarding the use of autologous ADSCs and clinically approved bone substitutes with or without BMPs for grafting of craniofacial bone defects (mandibular and maxillary bone)[128-130]. The combination of autologous ADSCs expanded in good manufacturing practice facilities and ceramic bone substitutes resulted in uneventful healing of bone defects. Cranioplasty of large calvarial defects using autologous ADSCs and β-transmission control protocol was reported as a useful method to replace massive bone loss[131]. Remarkably, all clinical reports regarding ADSC use involve the reconstruction of craniofacial bone defects. To our knowledge, recent years have not added to the reported clinical studies in this field. A list of current clinical trials registered on clinicaltrials.gov is available in Table 2.

**THE SUPPORTIVE ROLE OF ADSC - CELL THERAPY FOR BONE DISEASES AND FOR AUGMENTING FRACTURE HEALING**

The trophic role of ADSCs in tissue has been investigated for the treatment of metabolic bone diseases, such as osteoporosis. As a multifactorial disorder, osteoporosis has external and intrinsic determinants and is commonly associated with postmenopausal hormone depletion, ageing or long-term use of corticosteroid medication[132]. Local or systemic delivery of ADSC suspensions as cell therapy is sought to modulate bone resorption, increase bone formation and enhance BMD. The procedure relies less on the capability of infused cells to differentiate into osteoblastic lineages but rather on cytokine and growth factor release. This paracrine activity is expected to increase osteoprogenitor cell recruitment, proliferation, differentiation, ECM formation and mineralization[133]. Several preclinical studies report on the efficiency of autologous locally delivered ADSCs in improving bone strength in ovariectomized rats or in senescent mice[134,135]. Systemic human ADSC delivery in ovariectomized nude mice was as effective as oestrogen therapy in protecting trabecular bone loss, without evidence of ADSC engraftment[136].

Osteonecrosis of the femoral head (ONFH) is considered to be produced by apoptosis of mature osteocytes mainly due to impaired blood supply. ONFH affects a younger population, leading to collapse of the femoral head, a situation that requires total joint replacement. Unlike other forms of cell therapy, in ONFH, the use of stem cells started in clinics with the use of bone marrow aspirate concentrate as a modality to deliver progenitor cells locally after core decompression[137]. Most studies regarding the use of cultured MSCs for ONFH involve BMSCs; however, coculture with ADSCs was reported to have a synergistic effect mainly due to ADSC angiogenic potential[138]. Stem cells are commonly delivered within a supportive structure, such as fibrin gel or bone substitute for retaining the cells, as well as a modality to support or to prevent the collapse of the femoral head. Implanted cell contribution is probably rather paracrine because the local environment is not favorable for cell survival and differentiation after transplantation. ADSCs have been tested as a modality to locally deliver angiogenic factors. VEGF-transfected ADSCs in coculture with BMSCs were effective in inducing osteogenesis and angiogenesis *in vitro* and *in vivo*; however, this role needs to be further tested in ONFH animal models[139].

Delayed or impaired fracture healing can complicate up to 10% of total fracture cases[140]. Local risk factors can affect the quality and speed of bone healing, such as the severity of bone and soft tissue injury and the coexistence of multiple fractures or other associated trauma. Systemic factors, such as diabetes, obesity, malnutrition, smoking, and advanced age, are also known to represent a high risk for bone healing. ADSCs have been tested as a method for increasing the quality and decreasing the time of bone healing in animal models. Human ADSCs and their conditioned medium embedded in human blood plasma hydrogel were shown to increase fracture healing in surgically induced rat jaw fracture, demonstrating their paracrine effect in promoting bone union[141]. Local ADSC injection in healthy and diabetic rat femoral nonunions induced significant bone healing, as assessed by histology, compared to nontreated groups independent of RANK, RANKL, or OPG gene expression[142]. A combination of human ADSCs, cancellous bone grafts and chitosan gel consistently improved healing of the surgically induced nonunion of the femoral bone in rats, as confirmed by biomechanical and histological studies. ADSC presence was correlated with increased expression of VEGF and BMPs in the treated groups[143]. Autologous ADSCs delivered by local injection in atrophic nonunions in rat tibia resulted in significantly increased callus and solid bone union[144]. The report represents proof of concept of ADSC regenerative capabilities even in this difficult-to-treat variety of impaired fracture healing. The clinical use of ADSCs as a cell therapy for enhancing fracture healing has not yet been reported.

**WAT-DERIVED PLURIPOTENT CELL POPULATIONS: Multilineage differentiating stress-enduring CELLS AND DEDIFFERENTIATED FAT**

WAT is the source of two cell populations with tripoblastic differentiation potential and expression surface markers of pluripotency. Multilineage differentiating stress-enduring (MUSE) cells were initially obtained from dermal fibroblasts and BMSCs as stress-resistant populations[145]. WAT was soon identified as a plentiful source of MUSE cells that could be obtained by means of positive immune separation for mesenchymal surface antigen CD105 and pluripotency marker stage-specific embryonic antigen 1 (SSEA-1)[146]. A remarkable characteristic of these cells is their ability to grow in adherent and suspension culture conditions. When MUSE cells are cultured in a single-cell suspension, they form so-called “M clusters” with morphological resemblance to ESC or induced pluripotent stem cell (IPSC) embryoid bodies formed from embryonic stem cells (ESCs) or IPSCs. Since MUSE cells do not generate tumors after *in vivo* injection into severe combined immunodeficient (SCID) mice, they are considered safer than ESCs or IPSCs. MUSE cells are a small percentage of tissue-derived MSCs and are considered to be responsive to the regenerative potential of these populations. Their ability to migrate to damaged tissue and to spontaneously differentiate into cells that pertain to damaged tissue is regarded as having important potential in RM since unlikely ESC or IPSC preinduction to the respective lineage is not necessary[147]. MUSE cells have been tested in animal models for cardiovascular rescue (myocardial infarction) ischaemic stroke, lung injuries, kidney diseases and skin repair[148]. Their use in bone regeneration has not yet been tested; however, good results obtained in treating experimental patellar osteochondral defects might indicate a possible future application[149].

Mature cell dedifferentiation has been reported as a source of a pluripotent-like cell population. Mature adipocytes from WAT dedifferentiated *in vitro* by ceiling culture were found to revert to an undifferentiated phenotype and gain proliferative and differentiation capabilities[150]. Dedifferentiated fat (DFAT) cells have triploblastic differentiation potential *in vitro* and do not generate teratomas when injected into SCID mice[151]. DFAT cells are more homogenous than ADSCs and display mesenchymal surface markers and SSEA-3. DFAT was found to differentiate multiple cell lineages, including adipogenic, osteogenic, chondrogenic, myogenic, angiogenic and neurogenic lineages, and was tested in preclinical models of spinal cord injury rehabilitation of cardiac tissue after infarction[152,153]. DFAT cells were found to possess osteogenic capabilities when cocultured with periodontal ligament stem cells and might be a suitable cell source for periodontal regeneration[154]. DFAT cells display better differentiation capabilities, including osteogenic capabilities, than ADSCs from the same source. WAT-derived pluripotent cell populations are more homogenous than ADSCs and possess multilineage differentiation potential. Their prospective use for bone regeneration strategies is appealing and warrants more investigation.

**FAT GRAFTING AND BONE HEALING**

Not only cells but also WAT as a whole have been used in plastic and cosmetic surgery for aesthetic reasons but also for supporting wound healing and skin support[155].WAT has only recently been tested for its possible effect in supporting bone healing. Fragmented autologous WAT was shown to significantly increase mineralized matrix deposition in calvarial defects in rabbits compared to blood clot-treated and nontreated controls[156]. Fragmented WAT is investigated, as well as an autologous biomaterial that could be genetically modified to induce bone healing. In an *in vitro* study, genetically modified fragmented WAT overexpressing BMP-2 was shown to undergo mineralization in osteoinductive conditions[157]. The same team reported that the homodimer BMP-2 induced increased mineralization at lower doses compared to heterodimer BMP-2/6 or BMP-2/7; however, these findings need to be confirmed by *in vivo* studies[158]. WAT has been considered a modality to deliver microvascular grafts to healing bone defects to prevent atrophic nonunions. A thermoresponsive hydrogel (TRH) was used as a delivery system for WAT microfragments. However, local delivery of fragmented WAT-loaded TRH impaired bone formation in a murine model of bone defects, even though vascularization was improved. This undesirable outcome was thought to be produced by reduced VEGF expression in early phase bone healing, stressing the need for stage-specific delivery of bioactive factors[159].

**CONCLUSION**

Despite consistent research in recent decades, few clinical trials have tested the use of AT- or AT-derived cells for bone regeneration. To date, no clinically approved engineered product or cell therapy exists for treating impaired fracture healing, osteoporosis or ONFH. Particular challenges regarding cell heterogeneity and the type of cell used for different bone regenerative strategies are adding to the general challenges encountered by the development and approval of any advanced therapeutic medicinal product (ATMP). ADSC stemness characteristics are donor-dependent. The age of the donor has been thought to influence the quantity and quality of mesenchymal progenitors derived from WAT; however, conflicting reports exist in this respect. A decreased yield of SVF and ADSC colony-forming units per tissue, increased mitochondrial ROS production and impaired migratory and differentiation potential were reported for elderly donors in some studies[160,161]. Other studies, however, report similar characteristics of ADSCs derived from donors ranging from 8-62 years of age confirmed in a clinical case series where ADSCs were used for treating bone nonunions in combination with osteoconductive grafts[162]. The differences might be explained by the fact that studies reporting impaired ADSC characteristics in elderly individuals do not elucidate their possible coexisting diseases (such as diabetes, metabolic syndrome, and obesity)ADSCs derived from T2D patients were found to possess reduced viability and proliferative potential, exhibiting mitochondrial dysfunction and a senescence phenotype due to excessive mitochondrial ROS accumulation[163]. The T2D ADSC secretome was also modified with reduced VEGF, adiponectin, and chemokine (C-X-C motif) ligand-12 secretion and overproduction of leptin[164]. ADSCs derived from obese donors displayed reduced proliferative and differentiation potential compared to ADSCs from normal BMI donors. Obese ADSCs were shown to induce a proinflammatory phenotype in murine Mcfs and microglia, increasing the expression of proinflammatory genes and nitric oxide pathway activity while impairing their phagocytosis and migration[165]. Metabolic syndrome and T2D ADSCs have increased susceptibility to apoptosis and senescence with increased expression of senescence-associated β-galactosidase, a high level of anti-apoptotic protein B cell lymphoma-2 and decreased expression of the marker of proliferation Ki-67. These changes result in decreased proliferation, morphological changes with enlarged cellular bodies and nuclei and increased apoptosis of ADSC factors that affect the stemness of ADSCs derived from these donors[166]. WAT status obesity and weight loss, age and disease-related lipotrophy affect the quantity and quality of SVF and ADSCs that can be derived from autologous sources.

These findings underscore the need for thorough characterization of cells before their use for certain prospected clinical applications. Genomic and proteomic profiling of the ADSC phenotype, as well as their secretome, could identify biomarkers for selecting the appropriate cell source for a particular application in bone healing. This would result in possible test panels for determining whether autologous or allogenic cell sources are the best choice for the desired outcome. Modelling the desired profile for a specific application in bone healing (such as osteogenic potential and trophic and/or anti-inflammatory effects) would help select the cell phenotype that is more suitable for bone tissue engineering or cell therapy for fracture healing or other bone-specific diseases. Cell profiling for a projected ATMP would positively impact product characterization, standardized manufacturing and quality control.

Expanding the use of pluripotent cells from WAT, MUSE and DFAT cells, which are less donor-dependent and have increased osteogenic potential, could increase the chance for successful bone engineering strategies. Given the capability of MUSE cells to traffic, home and differentiate at the site of injury, a combined acellular scaffold with systemic or local MUSE delivery could represent a convenient modality for bone grafting and fracture healing. An important gap of knowledge still exists regarding the mutual interrelation between different AT types and bone in its normal and pathological states. Not only AT but also bone metabolism, fracture and the modality of fracture treatment can influence AT locally and systemically. BMP-2 treatment of long bone fractures in high- and low-fat diet-fed mice was shown to display increased vessel parameters and femoral adipocyte numbers irrespective of diet. Local BMP-2 delivery was shown to exert a diet-dependent effect on lung endothelial and bone marrow endothelial cells, influencing gene expression and *in vitro* tube formation capabilities[167]. These findings point out the necessity to investigate the complex interrelation between AT and bone from a systemic perspective. The role of BMAT in orchestrating local and systemic bone metabolism and bone healing and its interrelation with WAT and BAT need further investigation. Two recently registered clinical trials are salutary in this respect, as they are poised to compare WAT and BMAT characteristics in postmenopausal and osteoarthritic subjects (NCT03678831), as well as to model the complex interrelation between BMAT adipocytes and osteoblasts derived from osteoporotic patients (NCT04377880) (Table 2).

Multiple omics profiling of various cell populations and modelling their interactions in silico and *in vitro* will increase the understanding of intricate factors that govern AT and bone balance. The increased availability of organoids and organs on chip technologies that enable high-throughput experiments will enable the validation of computer models. These models will derive improved therapeutic targets for treating bone diseases and impaired fracture healing, as well as methods for using preventive measures for maintaining health in both compartments.

**ACKNOWLEDGEMENTS**

The author wishes to thank Prof. Dr. Veronica Mocanu MD, PhD, for the insightful discussions that induced the concept of the manuscript.

**REFERENCES**

1 **Ahima RS**. Adipose tissue as an endocrine organ. *Obesity (Silver Spring)* 2006; **14** Suppl 5: 242S-249S [PMID: 17021375 DOI: 10.1038/oby.2006.317]

2 **Booth A**, Magnuson A, Fouts J, Foster MT. Adipose tissue: an endocrine organ playing a role in metabolic regulation. *Horm Mol Biol Clin Investig* 2016; **26**: 25-42 [PMID: 26910750 DOI: 10.1515/hmbci-2015-0073]

3 **de Heredia FP**, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. *Proc Nutr Soc* 2012; **71**: 332-338 [PMID: 22429824 DOI: 10.1017/S0029665112000092]

4 **Akinci B**, Sahinoz M, Oral E. Lipodystrophy Syndromes: Presentation and Treatment. 2018 Apr 24. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000– [PMID: 29989768]

5 **Berry DC**, Stenesen D, Zeve D, Graff JM. The developmental origins of adipose tissue. *Development* 2013; **140**: 3939-3949 [PMID: 24046315 DOI: 10.1242/dev.080549]

6 **Billon N**, Monteiro MC, Dani C. Developmental origin of adipocytes: new insights into a pending question. *Biol Cell* 2008; **100**: 563-575 [PMID: 18793119 DOI: 10.1042/BC20080011]

7 **Bronner-Fraser M**. Neural crest cell formation and migration in the developing embryo. *FASEB J* 1994; **8**: 699-706 [PMID: 8050668 DOI: 10.1096/fasebj.8.10.8050668]

8 **Proença AR**, Sertié RA, Oliveira AC, Campaña AB, Caminhotto RO, Chimin P, Lima FB. New concepts in white adipose tissue physiology. *Braz J Med Biol Res* 2014; **47**: 192-205 [PMID: 24676492 DOI: 10.1590/1414-431X20132911]

9 **Vázquez-Vela ME**, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. *Arch Med Res* 2008; **39**: 715-728 [PMID: 18996284 DOI: 10.1016/j.arcmed.2008.09.005]

10 **Sebo ZL**, Rendina-Ruedy E, Ables GP, Lindskog DM, Rodeheffer MS, Fazeli PK, Horowitz MC. Bone Marrow Adiposity: Basic and Clinical Implications. *Endocr Rev* 2019; **40**: 1187-1206 [PMID: 31127816 DOI: 10.1210/er.2018-00138]

11 **Adamczak M**, Wiecek A. The adipose tissue as an endocrine organ. *Semin Nephrol* 2013; **33**: 2-13 [PMID: 23374889 DOI: 10.1016/j.semnephrol.2012.12.008]

12 **Shook B**, Rivera Gonzalez G, Ebmeier S, Grisotti G, Zwick R, Horsley V. The Role of Adipocytes in Tissue Regeneration and Stem Cell Niches. *Annu Rev Cell Dev Biol* 2016; **32**: 609-631 [PMID: 27146311 DOI: 10.1146/annurev-cellbio-111315-125426]

13 **Sennett R**, Rendl M. Mesenchymal-epithelial interactions during hair follicle morphogenesis and cycling. *Semin Cell Dev Biol* 2012; **23**: 917-927 [PMID: 22960356 DOI: 10.1016/j.semcdb.2012.08.011]

14 **Watabe R**, Yamaguchi T, Kabashima-Kubo R, Yoshioka M, Nishio D, Nakamura M. Leptin controls hair follicle cycling. *Exp Dermatol* 2014; **23**: 228-229 [PMID: 24494978 DOI: 10.1111/exd.12335]

15 **Salathia NS**, Shi J, Zhang J, Glynne RJ. An in vivo screen of secreted proteins identifies adiponectin as a regulator of murine cutaneous wound healing. *J Invest Dermatol* 2013; **133**: 812-821 [PMID: 23096717 DOI: 10.1038/jid.2012.374]

16 **Jin CE**, Xiao L, Ge ZH, Zhan XB, Zhou HX. Role of adiponectin in adipose tissue wound healing. *Genet Mol Res* 2015; **14**: 8883-8891 [PMID: 26345819 DOI: 10.4238/2015.August.3.11]

17 **Kawai K**, Kageyama A, Tsumano T, Nishimoto S, Fukuda K, Yokoyama S, Oguma T, Fujita K, Yoshimoto S, Yanai A, Kakibuchi M. Effects of adiponectin on growth and differentiation of human keratinocytes--implication of impaired wound healing in diabetes. *Biochem Biophys Res Commun* 2008; **374**: 269-273 [PMID: 18639522 DOI: 10.1016/j.bbrc.2008.07.045]

18 **Frank S**, Stallmeyer B, Kämpfer H, Kolb N, Pfeilschifter J. Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. *J Clin Invest* 2000; **106**: 501-509 [PMID: 10953025 DOI: 10.1172/JCI9148]

19 **Schmidt BA**, Horsley V. Intradermal adipocytes mediate fibroblast recruitment during skin wound healing. *Development* 2013; **140**: 1517-1527 [PMID: 23482487 DOI: 10.1242/dev.087593]

20 **Landskroner-Eiger S**, Park J, Israel D, Pollard JW, Scherer PE. Morphogenesis of the developing mammary gland: stage-dependent impact of adipocytes. *Dev Biol* 2010; **344**: 968-978 [PMID: 20599899 DOI: 10.1016/j.ydbio.2010.06.019]

21 **Joe AW**, Yi L, Natarajan A, Le Grand F, So L, Wang J, Rudnicki MA, Rossi FM. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. *Nat Cell Biol* 2010; **12**: 153-163 [PMID: 20081841 DOI: 10.1038/ncb2015]

22 **Uezumi A**, Fukada S, Yamamoto N, Ikemoto-Uezumi M, Nakatani M, Morita M, Yamaguchi A, Yamada H, Nishino I, Hamada Y, Tsuchida K. Identification and characterization of PDGFRα+ mesenchymal progenitors in human skeletal muscle. *Cell Death Dis* 2014; **5**: e1186 [PMID: 24743741 DOI: 10.1038/cddis.2014.161]

23 **Collao N**, Farup J, De Lisio M. Role of Metabolic Stress and Exercise in Regulating Fibro/Adipogenic Progenitors. *Front Cell Dev Biol* 2020; **8**: 9 [PMID: 32047748 DOI: 10.3389/fcell.2020.00009]

24 **Gimble JM**, Nuttall ME. The relationship between adipose tissue and bone metabolism. *Clin Biochem* 2012; **45**: 874-879 [PMID: 22429519 DOI: 10.1016/j.clinbiochem.2012.03.006]

25 **Fukushima N**, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, Takeda S, Takeuchi Y, Fukumoto S, Kangawa K, Nagata K, Kojima M. Ghrelin directly regulates bone formation. *J Bone Miner Res* 2005; **20**: 790-798 [PMID: 15824852 DOI: 10.1359/JBMR.041237]

26 **Astudillo P**, Ríos S, Pastenes L, Pino AM, Rodríguez JP. Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) characterizes by impaired leptin action. *J Cell Biochem* 2008; **103**: 1054-1065 [PMID: 17973271 DOI: 10.1002/jcb.21516]

27 **Thomas T**, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. *Endocrinology* 1999; **140**: 1630-1638 [PMID: 10098497 DOI: 10.1210/endo.140.4.6637]

28 **Holloway WR**, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, Gough TJ, Collier GR, Nicholson GC. Leptin inhibits osteoclast generation. *J Bone Miner Res* 2002; **17**: 200-209 [PMID: 11811550 DOI: 10.1359/jbmr.2002.17.2.200]

29 **Philbrick KA**, Wong CP, Branscum AJ, Turner RT, Iwaniec UT. Leptin stimulates bone formation in ob/ob mice at doses having minimal impact on energy metabolism. *J Endocrinol* 2017; **232**: 461-474 [PMID: 28057869 DOI: 10.1530/JOE-16-0484]

30 **Yamauchi T**, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med* 2001; **7**: 941-946 [PMID: 11479627 DOI: 10.1038/90984]

31 **Ryo M**, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. *Circ J* 2004; **68**: 975-981 [PMID: 15502375 DOI: 10.1253/circj.68.975]

32 **Huang CY**, Lee CY, Chen MY, Tsai HC, Hsu HC, Tang CH. Adiponectin increases BMP-2 expression in osteoblasts via AdipoR receptor signaling pathway. *J Cell Physiol* 2010; **224**: 475-483 [PMID: 20432444 DOI: 10.1002/jcp.22145]

33 **Sowa H**, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. *J Bone Miner Res* 2002; **17**: 1190-1199 [PMID: 12096832 DOI: 10.1359/jbmr.2002.17.7.1190]

34 **Pal China S**, Sanyal S, Chattopadhyay N. Adiponectin signaling and its role in bone metabolism. *Cytokine* 2018; **112**: 116-131 [PMID: 29937410 DOI: 10.1016/j.cyto.2018.06.012]

35 **Hou J**, He C, He W, Yang M, Luo X, Li C. Obesity and Bone Health: A Complex Link. *Front Cell Dev Biol* 2020; **8**: 600181 [PMID: 33409277 DOI: 10.3389/fcell.2020.600181]

36 **Pasarica M**, Gowronska-Kozak B, Burk D, Remedios I, Hymel D, Gimble J, Ravussin E, Bray GA, Smith SR. Adipose tissue collagen VI in obesity. *J Clin Endocrinol Metab* 2009; **94**: 5155-5162 [PMID: 19837927 DOI: 10.1210/jc.2009-0947]

37 **Furuhashi M**, Fucho R, Görgün CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. *J Clin Invest* 2008; **118**: 2640-2650 [PMID: 18551191 DOI: 10.1172/JCI34750]

38 **Feuerer M**, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. *Nat Med* 2009; **15**: 930-939 [PMID: 19633656 DOI: 10.1038/nm.2002]

39 **Wu AC**, Raggatt LJ, Alexander KA, Pettit AR. Unraveling macrophage contributions to bone repair. *Bonekey Rep* 2013; **2**: 373 [PMID: 25035807 DOI: 10.1038/bonekey.2013.107]

40 **Guihard P**, Danger Y, Brounais B, David E, Brion R, Delecrin J, Richards CD, Chevalier S, Rédini F, Heymann D, Gascan H, Blanchard F. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. *Stem Cells* 2012; **30**: 762-772 [PMID: 22267310 DOI: 10.1002/stem.1040]

41 **Gao F**, Lv TR, Zhou JC, Qin XD. Effects of obesity on the healing of bone fracture in mice. *J Orthop Surg Res* 2018; **13**: 145 [PMID: 29880016 DOI: 10.1186/s13018-018-0837-7]

42 **Cannon B**, Nedergaard J. Brown adipose tissue: function and physiological significance. *Physiol Rev* 2004; **84**: 277-359 [PMID: 14715917 DOI: 10.1152/physrev.00015.2003]

43 **Schulz TJ**, Tseng YH. Brown adipose tissue: development, metabolism and beyond. *Biochem J* 2013; **453**: 167-178 [PMID: 23805974 DOI: 10.1042/BJ20130457]

44 **Cypess AM**, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR. Identification and importance of brown adipose tissue in adult humans. *N Engl J Med* 2009; **360**: 1509-1517 [PMID: 19357406 DOI: 10.1056/NEJMoa0810780]

45 **Kontani Y**, Wang Y, Kimura K, Inokuma KI, Saito M, Suzuki-Miura T, Wang Z, Sato Y, Mori N, Yamashita H. UCP1 deficiency increases susceptibility to diet-induced obesity with age. *Aging Cell* 2005; **4**: 147-155 [PMID: 15924571 DOI: 10.1111/j.1474-9726.2005.00157.x]

46 **Lidell ME**, Enerbäck S. Brown adipose tissue and bone. *Int J Obes Suppl* 2015; **5**: S23-S27 [PMID: 27152171 DOI: 10.1038/ijosup.2015.7]

47 **Bredella MA**, Fazeli PK, Freedman LM, Calder G, Lee H, Rosen CJ, Klibanski A. Young women with cold-activated brown adipose tissue have higher bone mineral density and lower Pref-1 than women without brown adipose tissue: a study in women with anorexia nervosa, women recovered from anorexia nervosa, and normal-weight women. *J Clin Endocrinol Metab* 2012; **97**: E584-E590 [PMID: 22259053 DOI: 10.1210/jc.2011-2246]

48 **Lee P**, Brychta RJ, Collins MT, Linderman J, Smith S, Herscovitch P, Millo C, Chen KY, Celi FS. Cold-activated brown adipose tissue is an independent predictor of higher bone mineral density in women. *Osteoporos Int* 2013; **24**: 1513-1518 [PMID: 22890364 DOI: 10.1007/s00198-012-2110-y]

49 **Ponrartana S**, Aggabao PC, Hu HH, Aldrovandi GM, Wren TA, Gilsanz V. Brown adipose tissue and its relationship to bone structure in pediatric patients. *J Clin Endocrinol Metab* 2012; **97**: 2693-2698 [PMID: 22593587 DOI: 10.1210/jc.2012-1589]

50 **Calo E**, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA. Rb regulates fate choice and lineage commitment in vivo. *Nature* 2010; **466**: 1110-1114 [PMID: 20686481 DOI: 10.1038/nature09264]

51 **Olmsted-Davis E**, Gannon FH, Ozen M, Ittmann MM, Gugala Z, Hipp JA, Moran KM, Fouletier-Dilling CM, Schumara-Martin S, Lindsey RW, Heggeness MH, Brenner MK, Davis AR. Hypoxic adipocytes pattern early heterotopic bone formation. *Am J Pathol* 2007; **170**: 620-632 [PMID: 17255330 DOI: 10.2353/ajpath.2007.060692]

52 **Cederberg A**, Grønning LM, Ahrén B, Taskén K, Carlsson P, Enerbäck S. FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance. *Cell* 2001; **106**: 563-573 [PMID: 11551504 DOI: 10.1016/s0092-8674(01)00474-3]

53 **Rahman S**, Lu Y, Czernik PJ, Rosen CJ, Enerback S, Lecka-Czernik B. Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. *Endocrinology* 2013; **154**: 2687-2701 [PMID: 23696565 DOI: 10.1210/en.2012-2162]

54 **Horowitz MC**, Berry R, Holtrup B, Sebo Z, Nelson T, Fretz JA, Lindskog D, Kaplan JL, Ables G, Rodeheffer MS, Rosen CJ. Bone marrow adipocytes. *Adipocyte* 2017; **6**: 193-204 [PMID: 28872979 DOI: 10.1080/21623945.2017.1367881]

55 **Suchacki KJ**, Tavares AAS, Mattiucci D, Scheller EL, Papanastasiou G, Gray C, Sinton MC, Ramage LE, McDougald WA, Lovdel A, Sulston RJ, Thomas BJ, Nicholson BM, Drake AJ, Alcaide-Corral CJ, Said D, Poloni A, Cinti S, Macpherson GJ, Dweck MR, Andrews JPM, Williams MC, Wallace RJ, van Beek EJR, MacDougald OA, Morton NM, Stimson RH, Cawthorn WP. Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis. *Nat Commun* 2020; **11**: 3097 [PMID: 32555194 DOI: 10.1038/s41467-020-16878-2]

56 **Li Y**, Meng Y, Yu X. The Unique Metabolic Characteristics of Bone Marrow Adipose Tissue. *Front Endocrinol (Lausanne)* 2019; **10**: 69 [PMID: 30800100 DOI: 10.3389/fendo.2019.00069]

57 **Li J**, Chen X, Lu L, Yu X. The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. *Cytokine Growth Factor Rev* 2020; **52**: 88-98 [PMID: 32081538 DOI: 10.1016/j.cytogfr.2020.02.003]

58 **Suchacki KJ**, Cawthorn WP. Molecular Interaction of Bone Marrow Adipose Tissue with Energy Metabolism. *Curr Mol Biol Rep* 2018; **4**: 41-49 [PMID: 29888168 DOI: 10.1007/s40610-018-0096-8]

59 **Pierce JL**, Begun DL, Westendorf JJ, McGee-Lawrence ME. Defining osteoblast and adipocyte lineages in the bone marrow. *Bone* 2019; **118**: 2-7 [PMID: 29782940 DOI: 10.1016/j.bone.2018.05.019]

60 **Tratwal J**, Rojas-Sutterlin S, Bataclan C, Blum S, Naveiras O. Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment. *Best Pract Res Clin Endocrinol Metab* 2021; **35**: 101564 [PMID: 34417114 DOI: 10.1016/j.beem.2021.101564]

61 **Veldhuis-Vlug AG**, Rosen CJ. Clinical implications of bone marrow adiposity. *J Intern Med* 2018; **283**: 121-139 [PMID: 29211319 DOI: 10.1111/joim.12718]

62 **Wang H**, Leng Y, Gong Y. Bone Marrow Fat and Hematopoiesis. *Front Endocrinol (Lausanne)* 2018; **9**: 694 [PMID: 30546345 DOI: 10.3389/fendo.2018.00694]

63 **Hardaway AL**, Herroon MK, Rajagurubandara E, Podgorski I. Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. *Cancer Metastasis Rev* 2014; **33**: 527-543 [PMID: 24398857 DOI: 10.1007/s10555-013-9484-y]

64 **Moore SG**, Dawson KL. Red and yellow marrow in the femur: age-related changes in appearance at MR imaging. *Radiology* 1990; **175**: 219-223 [PMID: 2315484 DOI: 10.1148/radiology.175.1.2315484]

65 **Scheller EL**, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, Wu B, Ding SY, Bredella MA, Fazeli PK, Khoury B, Jepsen KJ, Pilch PF, Klibanski A, Rosen CJ, MacDougald OA. Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. *Nat Commun* 2015; **6**: 7808 [PMID: 26245716 DOI: 10.1038/ncomms8808]

66 **Muruganandan S**, Sinal CJ. The impact of bone marrow adipocytes on osteoblast and osteoclast differentiation. *IUBMB Life* 2014; **66**: 147-155 [PMID: 24638917 DOI: 10.1002/iub.1254]

67 **Muruganandan S**, Govindarajan R, Sinal CJ. Bone Marrow Adipose Tissue and Skeletal Health. *Curr Osteoporos Rep* 2018; **16**: 434-442 [PMID: 29855795 DOI: 10.1007/s11914-018-0451-y]

68 **Tencerova M**, Ferencakova M, Kassem M. Bone marrow adipose tissue: Role in bone remodeling and energy metabolism. *Best Pract Res Clin Endocrinol Metab* 2021; **35**: 101545 [PMID: 33966979 DOI: 10.1016/j.beem.2021.101545]

69 **Kokabu S**, Nguyen T, Ohte S, Sato T, Katagiri T, Yoda T, Rosen V. TLE3, transducing-like enhancer of split 3, suppresses osteoblast differentiation of bone marrow stromal cells. *Biochem Biophys Res Commun* 2013; **438**: 205-210 [PMID: 23880346 DOI: 10.1016/j.bbrc.2013.07.054]

70 **Hu L**, Yin C, Zhao F, Ali A, Ma J, Qian A. Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment. *Int J Mol Sci* 2018; **19** [PMID: 29370110 DOI: 10.3390/ijms19020360]

71 **Justesen J**, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. *Biogerontology* 2001; **2**: 165-171 [PMID: 11708718 DOI: 10.1023/a:1011513223894]

72 **Di Iorgi N**, Rosol M, Mittelman SD, Gilsanz V. Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. *J Clin Endocrinol Metab* 2008; **93**: 2281-2286 [PMID: 18381577 DOI: 10.1210/jc.2007-2691]

73 **L Newton A**, J Hanks L, Davis M, Casazza K. The relationships among total body fat, bone mineral content and bone marrow adipose tissue in early-pubertal girls. *Bonekey Rep* 2013; **2**: 315 [PMID: 23951544 DOI: 10.1038/bonekey.2013.49]

74 **Steinman J**, Shibli-Rahhal A. Anorexia Nervosa and Osteoporosis: Pathophysiology and Treatment. *J Bone Metab* 2019; **26**: 133-143 [PMID: 31555610 DOI: 10.11005/jbm.2019.26.3.133]

75 **Maïmoun L**, Renard E, Humbert L, Aouinti S, Mura T, Boudousq V, Lefebvre P, Mahadea K, Philibert P, de Santa-Barbara P, Avignon A, Guillaume S, Sultan A, Nocca D, Mariano-Goulart D. Modification of bone mineral density, bone geometry and volumetric BMD in young women with obesity. *Bone* 2021; **150**: 116005 [PMID: 33992821 DOI: 10.1016/j.bone.2021.116005]

76 **Martin PJ**, Haren N, Ghali O, Clabaut A, Chauveau C, Hardouin P, Broux O. Adipogenic RNAs are transferred in osteoblasts via bone marrow adipocytes-derived extracellular vesicles (EVs). *BMC Cell Biol* 2015; **16**: 10 [PMID: 25887582 DOI: 10.1186/s12860-015-0057-5]

77 **Heath D**, Momtaz D, Ghali A, Salazar L, Gibbons S, Hogue G. Obesity Increases Time to Union in Surgically Treated Pediatric Fracture Patients. *J Am Acad Orthop Surg Glob Res Rev* 2022; **6** [PMID: 34986128 DOI: 10.5435/JAAOSGlobal-D-21-00185]

78 **Brown ML**, Yukata K, Farnsworth CW, Chen DG, Awad H, Hilton MJ, O'Keefe RJ, Xing L, Mooney RA, Zuscik MJ. Delayed fracture healing and increased callus adiposity in a C57BL/6J murine model of obesity-associated type 2 diabetes mellitus. *PLoS One* 2014; **9**: e99656 [PMID: 24911161 DOI: 10.1371/journal.pone.0099656]

79 **Sun K**, Liu J, Lu N, Sun H, Ning G. Association between metabolic syndrome and bone fractures: a meta-analysis of observational studies. *BMC Endocr Disord* 2014; **14**: 13 [PMID: 24506931 DOI: 10.1186/1472-6823-14-13]

80 **Thorud JC**, Mortensen S, Thorud JL, Shibuya N, Maldonado YM, Jupiter DC. Effect of Obesity on Bone Healing After Foot and Ankle Long Bone Fractures. *J Foot Ankle Surg* 2017; **56**: 258-262 [PMID: 28109643 DOI: 10.1053/j.jfas.2016.11.010]

81 **King CM**, Hamilton GA, Cobb M, Carpenter D, Ford LA. Association between ankle fractures and obesity. *J Foot Ankle Surg* 2012; **51**: 543-547 [PMID: 22789485 DOI: 10.1053/j.jfas.2012.05.016]

82 **Sperelakis I**, Tsitoura E, Koutoulaki C, Mastrodimou S, Tosounidis TH, Spandidos DA, Antoniou KM, Kontakis G. Influence of reaming intramedullary nailing on MSC population after surgical treatment of patients with long bone fracture. *Mol Med Rep* 2020; **22**: 2521-2527 [PMID: 32705190 DOI: 10.3892/mmr.2020.11320]

83 **Mao AS**, Mooney DJ. Regenerative medicine: Current therapies and future directions. *Proc Natl Acad Sci U S A* 2015; **112**: 14452-14459 [PMID: 26598661 DOI: 10.1073/pnas.1508520112]

84 **Liao HT**, Chen CT. Osteogenic potential: Comparison between bone marrow and adipose-derived mesenchymal stem cells. *World J Stem Cells* 2014; **6**: 288-295 [PMID: 25126378 DOI: 10.4252/wjsc.v6.i3.288]

85 **Zuk PA**, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 2002; **13**: 4279-4295 [PMID: 12475952 DOI: 10.1091/mbc.e02-02-0105]

86 **Barba M**, Di Taranto G, Lattanzi W. Adipose-derived stem cell therapies for bone regeneration. *Expert Opin Biol Ther* 2017; **17**: 677-689 [PMID: 28374644 DOI: 10.1080/14712598.2017.1315403]

87 **Dominici M**, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; **8**: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905]

88 **Li H**, Zimmerlin L, Marra KG, Donnenberg VS, Donnenberg AD, Rubin JP. Adipogenic potential of adipose stem cell subpopulations. *Plast Reconstr Surg* 2011; **128**: 663-672 [PMID: 21572381 DOI: 10.1097/PRS.0b013e318221db33]

89 **Takashima S**, Usui S, Inoue O, Goten C, Yamaguchi K, Takeda Y, Cui S, Sakai Y, Hayashi K, Sakata K, Kawashiri MA, Takamura M. Myocyte-specific enhancer factor 2c triggers transdifferentiation of adipose tissue-derived stromal cells into spontaneously beating cardiomyocyte-like cells. *Sci Rep* 2021; **11**: 1520 [PMID: 33452355 DOI: 10.1038/s41598-020-80848-3]

90 **Sung MS**, Mun JY, Kwon O, Kwon KS, Oh DB. Efficient myogenic differentiation of human adipose-derived stem cells by the transduction of engineered MyoD protein. *Biochem Biophys Res Commun* 2013; **437**: 156-161 [PMID: 23810391 DOI: 10.1016/j.bbrc.2013.06.058]

91 **Tsuji W**, Rubin JP, Marra KG. Adipose-derived stem cells: Implications in tissue regeneration. *World J Stem Cells* 2014; **6**: 312-321 [PMID: 25126381 DOI: 10.4252/wjsc.v6.i3.312]

92 **Sung TC,** Heish CW, Hsin-Chung Lee H, Hsu JY, Wang CK, Wang JH, Zhu YR, Jen SH, Hsu ST, Hirad AH, Alarfaj AA, Higuchi A. 3D culturing of human adipose-derived stem cells enhances their pluripotency and differentiation abilities. *J Mat Sci Tech* 2021; **63**: 9-17 [DOI: 10.1016/j.jmst.2020.05.003]

93 **Riis S**, Stensballe A, Emmersen J, Pennisi CP, Birkelund S, Zachar V, Fink T. Mass spectrometry analysis of adipose-derived stem cells reveals a significant effect of hypoxia on pathways regulating extracellular matrix. *Stem Cell Res Ther* 2016; **7**: 52 [PMID: 27075204 DOI: 10.1186/s13287-016-0310-7]

94 **Kilroy GE**, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble JM. Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. *J Cell Physiol* 2007; **212**: 702-709 [PMID: 17477371 DOI: 10.1002/jcp.21068]

95 **Prautsch KM**, Schmidt A, Paradiso V, Schaefer DJ, Guzman R, Kalbermatten DF, Madduri S. Modulation of Human Adipose Stem Cells' Neurotrophic Capacity Using a Variety of Growth Factors for Neural Tissue Engineering Applications: Axonal Growth, Transcriptional, and Phosphoproteomic Analyses In Vitro. *Cells* 2020; **9** [PMID: 32839392 DOI: 10.3390/cells9091939]

96 **Kaewsuwan S**, Song SY, Kim JH, Sung JH. Mimicking the functional niche of adipose-derived stem cells for regenerative medicine. *Expert Opin Biol Ther* 2012; **12**: 1575-1588 [PMID: 22953993 DOI: 10.1517/14712598.2012.721763]

97 **Guillén MI**, Platas J, Pérez Del Caz MD, Mirabet V, Alcaraz MJ. Paracrine Anti-inflammatory Effects of Adipose Tissue-Derived Mesenchymal Stem Cells in Human Monocytes. *Front Physiol* 2018; **9**: 661 [PMID: 29904354 DOI: 10.3389/fphys.2018.00661]

98 **Taha S**, Volkmer E, Haas E, Alberton P, Straub T, David-Rus D, Aszodi A, Giunta R, Saller MM. Differences in the Inflammatory Response of White Adipose Tissue and Adipose-Derived Stem Cells. *Int J Mol Sci* 2020; **21** [PMID: 32041245 DOI: 10.3390/ijms21031086]

99 **Kocan B**, Maziarz A, Tabarkiewicz J, Ochiya T, Banaś-Ząbczyk A. Trophic Activity and Phenotype of Adipose Tissue-Derived Mesenchymal Stem Cells as a Background of Their Regenerative Potential. *Stem Cells Int* 2017; **2017**: 1653254 [PMID: 28757877 DOI: 10.1155/2017/1653254]

100 **Hu C**, Li L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. *J Cell Mol Med* 2018; **22**: 1428-1442 [PMID: 29392844 DOI: 10.1111/jcmm.13492]

101 **Zhang S**, Liu P, Chen L, Wang Y, Wang Z, Zhang B. The effects of spheroid formation of adipose-derived stem cells in a microgravity bioreactor on stemness properties and therapeutic potential. *Biomaterials* 2015; **41**: 15-25 [PMID: 25522961 DOI: 10.1016/j.biomaterials.2014.11.019]

102 **Kumar SA**, Delgado M, Mendez VE, Joddar B. Applications of stem cells and bioprinting for potential treatment of diabetes. *World J Stem Cells* 2019; **11**: 13-32 [PMID: 30705712 DOI: 10.4252/wjsc.v11.i1.13]

103 **Stanco D**, Boffito M, Bogni A, Puricelli L, Barrero J, Soldati G, Ciardelli G. 3D Bioprinting of Human Adipose-Derived Stem Cells and Their Tenogenic Differentiation in Clinical-Grade Medium. *Int J Mol Sci* 2020; **21** [PMID: 33218011 DOI: 10.3390/ijms21228694]

104 **Ceccarelli S**, Pontecorvi P, Anastasiadou E, Napoli C, Marchese C. Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application. *Front Cell Dev Biol* 2020; **8**: 236 [PMID: 32363193 DOI: 10.3389/fcell.2020.00236]

105 **Jeyaraman M**, John A, Koshy S, Ranjan R, Anudeep TC, Jain R, Swati K, Jha NK, Sharma A, Kesari KK, Prakash A, Nand P, Jha SK, Reddy PH. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. *Biochim Biophys Acta Mol Basis Dis* 2021; **1867**: 166014 [PMID: 33232817 DOI: 10.1016/j.bbadis.2020.166014]

106 **Sun Y**, Wan B, Wang R, Zhang B, Luo P, Wang D, Nie JJ, Chen D, Wu X. Mechanical Stimulation on Mesenchymal Stem Cells and Surrounding Microenvironments in Bone Regeneration: Regulations and Applications. *Front Cell Dev Biol* 2022; **10**: 808303 [PMID: 35127684 DOI: 10.3389/fcell.2022.808303]

107 **Park SH**, Sim WY, Min BH, Yang SS, Khademhosseini A, Kaplan DL. Chip-based comparison of the osteogenesis of human bone marrow- and adipose tissue-derived mesenchymal stem cells under mechanical stimulation. *PLoS One* 2012; **7**: e46689 [PMID: 23029565 DOI: 10.1371/journal.pone.0046689]

108 **Labusca L**, Herea DD, Danceanu CM, Minuti AE, Stavila C, Grigoras M, Gherca D, Stoian G, Ababei G, Chiriac H, Lupu N. The effect of magnetic field exposure on differentiation of magnetite nanoparticle-loaded adipose-derived stem cells. *Mater Sci Eng C Mater Biol Appl* 2020; **109**: 110652 [PMID: 32228923 DOI: 10.1016/j.msec.2020.110652]

109 **Schubert T**, Xhema D, Vériter S, Schubert M, Behets C, Delloye C, Gianello P, Dufrane D. The enhanced performance of bone allografts using osteogenic-differentiated adipose-derived mesenchymal stem cells. *Biomaterials* 2011; **32**: 8880-8891 [PMID: 21872925 DOI: 10.1016/j.biomaterials.2011.08.009]

110 **Levi B**, James AW, Nelson ER, Vistnes D, Wu B, Lee M, Gupta A, Longaker MT. Human adipose derived stromal cells heal critical size mouse calvarial defects. *PLoS One* 2010; **5**: e11177 [PMID: 20567510 DOI: 10.1371/journal.pone.0011177]

111 **Liu J**, Zhou P, Long Y, Huang C, Chen D. Repair of bone defects in rat radii with a composite of allogeneic adipose-derived stem cells and heterogeneous deproteinized bone. *Stem Cell Res Ther* 2018; **9**: 79 [PMID: 29587852 DOI: 10.1186/s13287-018-0817-1]

112 **Murphy CM**, O'Brien FJ, Little DG, Schindeler A. Cell-scaffold interactions in the bone tissue engineering triad. *Eur Cell Mater* 2013; **26**: 120-132 [PMID: 24052425 DOI: 10.22203/ecm.v026a09]

113 **Storti G**, Scioli MG, Kim BS, Orlandi A, Cervelli V. Adipose-Derived Stem Cells in Bone Tissue Engineering: Useful Tools with New Applications. *Stem Cells Int* 2019; **2019**: 3673857 [PMID: 31781238 DOI: 10.1155/2019/3673857]

114 **Lyu CQ**, Lu JY, Cao CH, Luo D, Fu YX, He YS, Zou DR. Induction of Osteogenic Differentiation of Human Adipose-Derived Stem Cells by a Novel Self-Supporting Graphene Hydrogel Film and the Possible Underlying Mechanism. *ACS Appl Mater Interfaces* 2015; **7**: 20245-20254 [PMID: 26323463 DOI: 10.1021/acsami.5b05802]

115 **Zhang X**, Guo J, Zhou Y, Wu G. The roles of bone morphogenetic proteins and their signaling in the osteogenesis of adipose-derived stem cells. *Tissue Eng Part B Rev* 2014; **20**: 84-92 [PMID: 23758605 DOI: 10.1089/ten.TEB.2013.0204]

116 **Liao HT**, Tsai MJ, Brahmayya M, Chen JP. Bone Regeneration Using Adipose-Derived Stem Cells in Injectable Thermo-Gelling Hydrogel Scaffold Containing Platelet-Rich Plasma and Biphasic Calcium Phosphate. *Int J Mol Sci* 2018; **19** [PMID: 30150580 DOI: 10.3390/ijms19092537]

117 **Kazem-Arki M**, Kabiri M, Rad I, Roodbari NH, Hosseinpoor H, Mirzaei S, Parivar K, Hanaee-Ahvaz H. Enhancement of osteogenic differentiation of adipose-derived stem cells by PRP modified nanofibrous scaffold. *Cytotechnology* 2018; **70**: 1487-1498 [PMID: 30083791 DOI: 10.1007/s10616-018-0226-4]

118 **Romagnoli C**, Brandi ML. Adipose mesenchymal stem cells in the field of bone tissue engineering. *World J Stem Cells* 2014; **6**: 144-152 [PMID: 24772241 DOI: 10.4252/wjsc.v6.i2.144]

119 **Lim S**, Cho H, Lee E, Won Y, Kim C, Ahn W, Lee E, Son Y. Osteogenic stimulation of human adipose-derived stem cells by pre-treatment with fibroblast growth factor 2. *Cell Tissue Res* 2016; **364**: 137-147 [PMID: 26547859 DOI: 10.1007/s00441-015-2311-8]

120 **Xiong M**, Zhang Q, Hu W, Zhao C, Lv W, Yi Y, Wu Y, Wu M. Exosomes From Adipose-Derived Stem Cells: The Emerging Roles and Applications in Tissue Regeneration of Plastic and Cosmetic Surgery. *Front Cell Dev Biol* 2020; **8**: 574223 [PMID: 33015067 DOI: 10.3389/fcell.2020.574223]

121 **Yang S**, Guo S, Tong S, Sun X. Promoting Osteogenic Differentiation of Human Adipose-Derived Stem Cells by Altering the Expression of Exosomal miRNA. *Stem Cells Int* 2019; **2019**: 1351860 [PMID: 31354836 DOI: 10.1155/2019/1351860]

122 **Xie Q**, Wei W, Ruan J, Ding Y, Zhuang A, Bi X, Sun H, Gu P, Wang Z, Fan X. Effects of miR-146a on the osteogenesis of adipose-derived mesenchymal stem cells and bone regeneration. *Sci Rep* 2017; **7**: 42840 [PMID: 28205638 DOI: 10.1038/srep42840]

123 **Liao YH**, Chang YH, Sung LY, Li KC, Yeh CL, Yen TC, Hwang SM, Lin KJ, Hu YC. Osteogenic differentiation of adipose-derived stem cells and calvarial defect repair using baculovirus-mediated co-expression of BMP-2 and miR-148b. *Biomaterials* 2014; **35**: 4901-4910 [PMID: 24674465 DOI: 10.1016/j.biomaterials.2014.02.055]

124 **Qureshi AT**, Doyle A, Chen C, Coulon D, Dasa V, Del Piero F, Levi B, Monroe WT, Gimble JM, Hayes DJ. Photoactivated miR-148b-nanoparticle conjugates improve closure of critical size mouse calvarial defects. *Acta Biomater* 2015; **12**: 166-173 [PMID: 25462528 DOI: 10.1016/j.actbio.2014.10.010]

125 **Deng Y**, Zhou H, Zou D, Xie Q, Bi X, Gu P, Fan X. The role of miR-31-modified adipose tissue-derived stem cells in repairing rat critical-sized calvarial defects. *Biomaterials* 2013; **34**: 6717-6728 [PMID: 23768901 DOI: 10.1016/j.biomaterials.2013.05.042]

126 **Nordberg RC**, Bodle JC, Loboa EG. Mechanical Stimulation of Adipose-Derived Stem Cells for Functional Tissue Engineering of the Musculoskeletal System via Cyclic Hydrostatic Pressure, Simulated Microgravity, and Cyclic Tensile Strain. *Methods Mol Biol* 2018; **1773**: 215-230 [PMID: 29687393 DOI: 10.1007/978-1-4939-7799-4\_18]

127 **Lendeckel S**, Jödicke A, Christophis P, Heidinger K, Wolff J, Fraser JK, Hedrick MH, Berthold L, Howaldt HP. Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. *J Craniomaxillofac Surg* 2004; **32**: 370-373 [PMID: 15555520 DOI: 10.1016/j.jcms.2004.06.002]

128 **Kulakov AA**, Goldshtein DV, Grigoryan AS, Rzhaninova AA, Alekseeva IS, Arutyunyan IV, Volkov AV. Clinical study of the efficiency of combined cell transplant on the basis of multipotent mesenchymal stromal adipose tissue cells in patients with pronounced deficit of the maxillary and mandibulary bone tissue. *Bull Exp Biol Med* 2008; **146**: 522-525 [PMID: 19489333 DOI: 10.1007/s10517-009-0322-8]

129 **Sándor GK**, Tuovinen VJ, Wolff J, Patrikoski M, Jokinen J, Nieminen E, Mannerström B, Lappalainen OP, Seppänen R, Miettinen S. Adipose stem cell tissue-engineered construct used to treat large anterior mandibular defect: a case report and review of the clinical application of good manufacturing practice-level adipose stem cells for bone regeneration. *J Oral Maxillofac Surg* 2013; **71**: 938-950 [PMID: 23375899 DOI: 10.1016/j.joms.2012.11.014]

130 **Mesimäki K**, Lindroos B, Törnwall J, Mauno J, Lindqvist C, Kontio R, Miettinen S, Suuronen R. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells. *Int J Oral Maxillofac Surg* 2009; **38**: 201-209 [PMID: 19168327 DOI: 10.1016/j.ijom.2009.01.001]

131 **Thesleff T**, Lehtimäki K, Niskakangas T, Mannerström B, Miettinen S, Suuronen R, Öhman J. Cranioplasty with adipose-derived stem cells and biomaterial: a novel method for cranial reconstruction. *Neurosurgery* 2011; **68**: 1535-1540 [PMID: 21336223 DOI: 10.1227/NEU.0b013e31820ee24e]

132 **Clynes MA**, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. *Br Med Bull* 2020; **133**: 105-117 [PMID: 32282039 DOI: 10.1093/bmb/ldaa005]

133 **Phetfong J**, Sanvoranart T, Nartprayut K, Nimsanor N, Seenprachawong K, Prachayasittikul V, Supokawej A. Osteoporosis: the current status of mesenchymal stem cell-based therapy. *Cell Mol Biol Lett* 2016; **21**: 12 [PMID: 28536615 DOI: 10.1186/s11658-016-0013-1]

134 **Uri O**, Behrbalk E, Folman Y. Local implantation of autologous adipose-derived stem cells increases femoral strength and bone density in osteoporotic rats: A randomized controlled animal study. *J Orthop Surg (Hong Kong)* 2018; **26**: 2309499018799534 [PMID: 30235971 DOI: 10.1177/2309499018799534]

135 **Mirsaidi A**, Genelin K, Vetsch JR, Stanger S, Theiss F, Lindtner RA, von Rechenberg B, Blauth M, Müller R, Kuhn GA, Hofmann Boss S, Ebner HL, Richards PJ. Therapeutic potential of adipose-derived stromal cells in age-related osteoporosis. *Biomaterials* 2014; **35**: 7326-7335 [PMID: 24933514 DOI: 10.1016/j.biomaterials.2014.05.016]

136 **Cho SW**, Sun HJ, Yang JY, Jung JY, Choi HJ, An JH, Kim SW, Kim SY, Park KJ, Shin CS. Human adipose tissue-derived stromal cell therapy prevents bone loss in ovariectomized nude mouse. *Tissue Eng Part A* 2012; **18**: 1067-1078 [PMID: 22220675 DOI: 10.1089/ten.TEA.2011.0355]

137 **Hernigou P**, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. *Clin Orthop Relat Res* 2002: 14-23 [PMID: 12461352 DOI: 10.1097/00003086-200212000-00003]

138 **Kim KI**, Park S, Im GI. Osteogenic differentiation and angiogenesis with cocultured adipose-derived stromal cells and bone marrow stromal cells. *Biomaterials* 2014; **35**: 4792-4804 [PMID: 24655782 DOI: 10.1016/j.biomaterials.2014.02.048]

139 **Kang ML**, Kim JE, Im GI. Vascular endothelial growth factor-transfected adipose-derived stromal cells enhance bone regeneration and neovascularization from bone marrow stromal cells. *J Tissue Eng Regen Med* 2017; **11**: 3337-3348 [PMID: 28198165 DOI: 10.1002/term.2247]

140 **Hernandez RK**, Do TP, Critchlow CW, Dent RE, Jick SS. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. *Acta Orthop* 2012; **83**: 653-660 [PMID: 23140093 DOI: 10.3109/17453674.2012.747054]

141 **Linero I**, Chaparro O. Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration. *PLoS One* 2014; **9**: e107001 [PMID: 25198551 DOI: 10.1371/journal.pone.0107001]

142 **Olçar HA**, Halıcı M, Kafadar İH, Karaman İ, Lekesizcan A, Gönen ZB. Can injection of adipose stem cells to non-union zone increase bone union? Experimental rat study. *Jt Dis Relat Surg* 2020; **31**: 20-27 [PMID: 32160489 DOI: 10.5606/ehc.2020.71270]

143 **Mousaei Ghasroldasht M**, Matin MM, Kazemi Mehrjerdi H, Naderi-Meshkin H, Moradi A, Rajabioun M, Alipour F, Ghasemi S, Zare M, Mirahmadi M, Bidkhori HR, Bahrami AR. Application of mesenchymal stem cells to enhance non-union bone fracture healing. *J Biomed Mater Res A* 2019; **107**: 301-311 [PMID: 29673055 DOI: 10.1002/jbm.a.36441]

144 **Jalal MMK**, Wallace RJ, Peault B, Simpson AHRW. Assessment of the quality of bone repair after autologous fat-derived mesenchymal stem cell (MSC) injection in a clinically relevant model of atrophic nonunion. Proceedings of the Scottish Committee for Orthopaedics and Trauma (SCOT) August 2020 Meeting; 2020 Aug 28; Online. London: Bone & Joint Publishing, 2021: **103-B**

145 **Kuroda Y**, Kitada M, Wakao S, Nishikawa K, Tanimura Y, Makinoshima H, Goda M, Akashi H, Inutsuka A, Niwa A, Shigemoto T, Nabeshima Y, Nakahata T, Nabeshima Y, Fujiyoshi Y, Dezawa M. Unique multipotent cells in adult human mesenchymal cell populations. *Proc Natl Acad Sci U S A* 2010; **107**: 8639-8643 [PMID: 20421459 DOI: 10.1073/pnas.0911647107]

146 **Kitada M**, Wakao S, Dezawa M. Muse cells and induced pluripotent stem cell: implication of the elite model. *Cell Mol Life Sci* 2012; **69**: 3739-3750 [PMID: 22527723 DOI: 10.1007/s00018-012-0994-5]

147 **Dezawa M**. Muse Cells Provide the Pluripotency of Mesenchymal Stem Cells: Direct Contribution of Muse Cells to Tissue Regeneration. *Cell Transplant* 2016; **25**: 849-861 [PMID: 26884346 DOI: 10.3727/096368916X690881]

148 **Cao J**, Yang Z, Xiao R, Pan B. Regenerative potential of pluripotent nontumorgenetic stem cells: Multilineage differentiating stress enduring cells (Muse cells). *Regen Ther* 2020; **15**: 92-96 [PMID: 33426206 DOI: 10.1016/j.reth.2020.04.011]

149 **Mahmoud EE**, Kamei N, Shimizu R, Wakao S, Dezawa M, Adachi N, Ochi M. Therapeutic Potential of Multilineage-Differentiating Stress-Enduring Cells for Osteochondral Repair in a Rat Model. *Stem Cells Int* 2017; **2017**: 8154569 [PMID: 29312455 DOI: 10.1155/2017/8154569]

150 **Matsumoto T**, Kano K, Kondo D, Fukuda N, Iribe Y, Tanaka N, Matsubara Y, Sakuma T, Satomi A, Otaki M, Ryu J, Mugishima H. Mature adipocyte-derived dedifferentiated fat cells exhibit multilineage potential. *J Cell Physiol* 2008; **215**: 210-222 [PMID: 18064604 DOI: 10.1002/jcp.21304]

151 **Jumabay M**, Boström KI. Dedifferentiated fat cells: A cell source for regenerative medicine. *World J Stem Cells* 2015; **7**: 1202-1214 [PMID: 26640620 DOI: 10.4252/wjsc.v7.i10.1202]

152 **Barbuti A**. The 'hearty' fat: adipocytes as a source of functional cardiomyocytes. *Cardiovasc Res* 2010; **85**: 1-2 [PMID: 19887381 DOI: 10.1093/cvr/cvp358]

153 **Ohta Y**, Takenaga M, Tokura Y, Hamaguchi A, Matsumoto T, Kano K, Mugishima H, Okano H, Igarashi R. Mature adipocyte-derived cells, dedifferentiated fat cells (DFAT), promoted functional recovery from spinal cord injury-induced motor dysfunction in rats. *Cell Transplant* 2008; **17**: 877-886 [PMID: 19069631 DOI: 10.3727/096368908786576516]

154 **Kishimoto N**, Momota Y, Hashimoto Y, Tatsumi S, Ando K, Omasa T, Kotani J. The osteoblastic differentiation ability of human dedifferentiated fat cells is higher than that of adipose stem cells from the buccal fat pad. *Clin Oral Investig* 2014; **18**: 1893-1901 [PMID: 24362590 DOI: 10.1007/s00784-013-1166-1]

155 **Fu X**, Fang L, Li H, Li X, Cheng B, Sheng Z. Adipose tissue extract enhances skin wound healing. *Wound Repair Regen* 2007; **15**: 540-548 [PMID: 17650098 DOI: 10.1111/j.1524-475X.2007.00262.x]

156 **Oliveira LD**, Giovanini AF, Abuabara A, Klug LG, Gonzaga CC, Zielak JC, Urban CD, Deliberador TM. Fragmented adipose tissue graft for bone healing: histological and histometric study in rabbits' calvaria. *Med Oral Patol Oral Cir Bucal* 2013; **18**: e510-e515 [PMID: 23524416 DOI: 10.4317/medoral.18407]

157 **Ren B**, Betz VM, Thirion C, Salomon M, Klar RM, Jansson V, Müller PE, Betz OB. Gene activated adipose tissue fragments as advanced autologous biomaterials for bone regeneration: osteogenic differentiation within the tissue and implications for clinical translation. *Sci Rep* 2019; **9**: 224 [PMID: 30659209 DOI: 10.1038/s41598-018-36283-6]

158 **Betz VM**, Ren B, Betz OB, Jansson V, Müller PE. Osteoinduction within adipose tissue fragments by heterodimeric bone morphogenetic Proteins-2/6 and -2/7 versus homodimeric bone morphogenetic protein-2: Therapeutic implications for bone regeneration. *J Gene Med* 2021; **23**: e3311 [PMID: 33527563 DOI: 10.1002/jgm.3311]

159 **Orth M**, Altmeyer MAB, Scheuer C, Braun BJ, Holstein JH, Eglin D, D'Este M, Histing T, Laschke MW, Pohlemann T, Menger MD. Effects of locally applied adipose tissue-derived microvascular fragments by thermoresponsive hydrogel on bone healing. *Acta Biomater* 2018; **77**: 201-211 [PMID: 30030175 DOI: 10.1016/j.actbio.2018.07.029]

160 **Liu M**, Lei H, Dong P, Fu X, Yang Z, Yang Y, Ma J, Liu X, Cao Y, Xiao R. Adipose-Derived Mesenchymal Stem Cells from the Elderly Exhibit Decreased Migration and Differentiation Abilities with Senescent Properties. *Cell Transplant* 2017; **26**: 1505-1519 [PMID: 29113467 DOI: 10.1177/0963689717721221]

161 **Kornicka K**, Marycz K, Tomaszewski KA, Marędziak M, Śmieszek A. The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process. *Oxid Med Cell Longev* 2015; **2015**: 309169 [PMID: 26246868 DOI: 10.1155/2015/309169]

162 **Vériter S**, André W, Aouassar N, Poirel HA, Lafosse A, Docquier PL, Dufrane D. Human Adipose-Derived Mesenchymal Stem Cells in Cell Therapy: Safety and Feasibility in Different "Hospital Exemption" Clinical Applications. *PLoS One* 2015; **10**: e0139566 [PMID: 26485394 DOI: 10.1371/journal.pone.0139566]

163 **Dufrane D**. Impact of Age on Human Adipose Stem Cells for Bone Tissue Engineering. *Cell Transplant* 2017; **26**: 1496-1504 [PMID: 29113460 DOI: 10.1177/0963689717721203]

164 **Alicka M**, Major P, Wysocki M, Marycz K. Adipose-Derived Mesenchymal Stem Cells Isolated from Patients with Type 2 Diabetes Show Reduced "Stemness" through an Altered Secretome Profile, Impaired Anti-Oxidative Protection, and Mitochondrial Dynamics Deterioration. *J Clin Med* 2019; **8** [PMID: 31151180 DOI: 10.3390/jcm8060765]

165 **Harrison MAA**, Wise RM, Benjamin BP, Hochreiner EM, Mohiuddin OA, Bunnell BA. Adipose-Derived Stem Cells from Obese Donors Polarize Macrophages and Microglia toward a Pro-Inflammatory Phenotype. *Cells* 2020; **10** [PMID: 33375695 DOI: 10.3390/cells10010026]

166 **Kornicka K**, Houston J, Marycz K. Dysfunction of Mesenchymal Stem Cells Isolated from Metabolic Syndrome and Type 2 Diabetic Patients as Result of Oxidative Stress and Autophagy may Limit Their Potential Therapeutic Use. *Stem Cell Rev Rep* 2018; **14**: 337-345 [PMID: 29611042 DOI: 10.1007/s12015-018-9809-x]

167 **Bhatti FUR**, Dadwal UC, Valuch CR, Tewari NP, Awosanya OD, de Andrade Staut C, Sun S, Mendenhall SK, Perugini AJ 3rd, Nagaraj RU, Battina HL, Nazzal MK, Blosser RJ, Maupin KA, Childress PJ, Li J, Kacena MA. The effects of high fat diet, bone healing, and BMP-2 treatment on endothelial cell growth and function. *Bone* 2021; **146**: 115883 [PMID: 33581374 DOI: 10.1016/j.bone.2021.115883]

168 **Calcagni M**. Development of bone grafts using adipose-derived stem cells and different scaffolds. [accessed 2021 June 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01218945 ClinicalTrials.gov Identifier: NCT01218945

169 **Saxer F**, Jakob M. Effectiveness of adipose tissue derived mesenchymal stem cells as osteogenic component in composite grafts (ROBUST). [accessed 2021 June 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01532076 ClinicalTrials.gov Identifier: NCT01532076

170 **Yoon KS**. Autologous adipose tissue-derived mesenchymal stem cells transplantation in patient with avascular necrosis of the femoral head. [accessed 2021 June 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01643655 ClinicalTrials.gov Identifier: NCT01643655

171 **Gourabi H**, Aghdami N, Emaddedin M, Ahmadi A, Ghorbani M, Farhadi A. Allogeneic mesenchymal stem cell transplantation in tibial closed diaphyseal fractures. [accessed 2021 June 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02140528 ClinicalTrials.gov Identifier: NCT02140528

172 **Sierra RJ**. Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis. [accessed 2021 June 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03269409 ClinicalTrials.gov Identifier: NCT03269409

173 **Dilogo IH**. Allogenic mesenchymal stem cell for bone defect or non union fracture (AMSC). [accessed 2021 June 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT02307435 ClinicalTrials.gov Identifier: NCT02307435

174 **Pasquier G**. Characteristics of marrow fatty cells in the ageing of bone and joints, osteoarthritis and osteoporosis (MEDADIPO). [accessed 2021 June 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT03678831?term=NCT03678831&draw=2&rank=1 ClinicalTrials.gov Identifier: NCT03678831

175 **Fodzo E**. Development of cellular models for osteoblast response study to adipocytic secretions in an osteoporosis context (ROSA). [accessed 2021 June 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04377880 Identifier: NCT04377880

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** July 17, 2021

**First decision:** August 9, 2021

**Article in press:** May 27, 2022

**Specialty type:** Cell and tissue engineering

**Country/Territory of origin:** Romania

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kienhui C, Malaysia **A-Editor:** Naserian S, France **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ

**Figure Legends**



**Figure 1 Adipose-derived mesenchymal stem cell osteogenesis under magnetomechanical stimulation.** A: Osteogenesis of adipose-derived mesenchymal stem cells (ADSCs) loaded with micronutrient powders (MNPs) exposed to alternating MFs; B: Osteogenesis of ADSCs without MNPs exposed to MFs assessed with OsteoImage® Lonza showing green fluorescence for the deposited calcified extracellular matrix.

**Table 1 Factors that influence adipose-derived mesenchymal stem cells secretome content and release[99-101]**

|  |  |  |  |
| --- | --- | --- | --- |
| **Donor** | **Tissue** | **Culture conditions** | **Cell manipulation** |
| Species | Type (sWAT, vWAT) | 2D *versus* 3D (spheroid culture, cell sheets), suspension culture | Preconditioning (IFN-γ, TNF-α, LPS) |
| Age | Anatomic location (abdominal, brachial, mammary) | Hypoxia | Differentiation (osteogenic, adipogenic) |
| BMD (obesity) | Method of procurement (lipectomy, liposuction) | Plating density, co-culture | Physical factors (electromagnetic fields, pulsed electromagnetic fields) |
| Disease (T2D, metabolic syndrome, lipodystrophy) | Methods of tissue processing, enzymatic digestion, mechanical trituration | Media formulation (serum containing versus serum free, growth factor addition) |  |

T2D: Type 2 diabetes mellitus; sWAT: Subcutaneous white adipose tissue; vWAT: Visceral white adipose tissue; IFN-γ: Interferon gamma; TNF-α: Tumor necrosis factor alpha; LPS: Lipopolysaccharides; BMD: Bone mineral density.

**Table 2 Clinical trials using adipose-derived mesenchymal stem cells for bone regeneration registered on clinicaltrials.gov (June 2021)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Trial registration** | **Ref.** | **Study design** | **Group/cohort** | **Intervention** | **Location** | **Status** |
| NCT01218945 | Calcagni[168] | Observational/prospective | Overweight, non-metabolic disease, 17-80 yr | To pre-engineer large synthetic bone grafts and study the vascularization process *in vivo* | University of Zurich, Switzerland | Completed December 2012 |
| NCT01532076 | Saxer and Jakob[169] | Allocation: Randomized. Intervention model: Parallel assignment. Masking: Single (outcomes assessor). Primary purpose: Treatment | Patients with osteoporotic fractures, age 18-70 yr | Cellularized composite graft augmentation liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules compared to acellular grafts | University Hospital, Basel, Switzerland | Terminated/slow recruitment rate/last update 17 September 2014 |
| NCT01643655 | Yoon[170] | Allocation: N/A. Intervention model: Single group assignment. Masking: None (open label). Primary purpose: Treatment | Avascular necrosis femoral head Steinberg I-III/pre-collapse, age 17-70 yr | Autologous adipose tissue-derived MSCs transplantation into the femoral head/infusion of autologous adipose-derived mesenchymal stem cells. Dose: 1 × 108 cells/3 mL | R-Bio SMG-SNU Boramae Medical Center | Recruitment completed/last update 31 August 2017 |
| NCT02140528 | Gourabi *et al*[171] | Allocation: Randomized. Intervention model: Parallel assignment. Masking: Double (participant, investigator). Primary purpose: Treatment | Closed shaft tibial fracture, age 18-65 yr | Injection of adipose-derived mesenchymal stem cell in the site of tibia fracture. Other name: Stem cell transplantation compared to Placebo | Royan Institute Tehran, Iran | Completed/last update 27 April 2017 |
| NCT03269409 | Sierra[172] | Interventional, allocation: Randomized. Intervention model: Parallel assignment. Masking: Quadruple (participant, care provider, investigator, outcomes assessor). Primary purpose: Treatment | Patients with ONFH pre-collapse, non-posttraumatic, 22-70 yr of age | Adipose-derived regenerative cells harvested through autologous liposuction processed using the Celution 800/GP System (Cytori Therapeutics) transplanted into the femoral head after standard of care hip decompression compared to standard decompression and Ringer solution | Mayo Clinic, United States | Suspended (updating study protocol, consent form and study SOP protocol) March 2021 |
| NCT02307435 | Dilogo[173] | Allocation: N/A. Intervention model: Single group assignment. Masking: None (open label). Primary purpose: Treatment | Fracture nonunion metaphyseal fibrous defect, age 19-30 yr | Experimental: Implantation group implantation group will receive ADSC/UCMASC/BMSCs and HA-CaSO4. Intervention: Biological: MSC | University of Indonesia, Jakarta | Unknown/last update 4 December 2014 |
| NCT03678831 | Pasquier[174] | Observational, case-control prospective | Arthritic post-menopausal patients with knee prosthetic replacement | Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee | University Hospital, Lille, France | Recruiting/April 2021 |
| NCT04377880 | Fodzo[175] | Observational study | Osteoporotic patients undergoing total joint arthroplasty | Osteoblastic response to medullary adipocytes of commercial origin analysed by gene expression and correlation with clinical data regarding osteoporosis and microtomography | University Hospital, Lille | May 2021 |

ADSC: Adipose-derived mesenchymal stem cells; UCMASC: Umbilical cord mesenchymal stem cell; BMSC: Bone marrow stem cell; MSC: Marrow stem cell; ONFH: Osteonecrosis of the femoral head; SOP: Standard operating procedures; SVF: Stromal vascular fraction.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**